Table of Contents

SECURITIES AND EXCHANGE COMISSION

Washington, D.C. 20549

 


 

FORM 10-QSB

 


 

[Mark One]

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended SEPTEMBER 30, 2004

 

¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from              to             

 

Commission File Number: 0-25203

 


 

OmniComm Systems, Inc.

(Name of Small Business Issuer in its Charter)

 


 

Delaware   11-3349762
State of Incorporation   IRS Federal Employer Identification Number
2555 Davie Road, Suite 110-B, Davie, Florida   33317
Address of Principal Office   Zip Code

 

Registrant’s Telephone Number: 954.473.1254

 


 

Indicate by check mark whether the Registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes   x     NO   ¨

 

The number of shares outstanding of each of the issuer’s classes of common equity as of September 30, 2004: 22,679,277 common stock $.001 par value.

 



Table of Contents

FINANCIAL STATEMENTS

 

Table of Contents

 

PART I. FINANCIAL INFORMATION

   

Item 1. Unaudited Consolidated Financial Statements

   

Consolidated Balance Sheets

 

1

Consolidated Income Statements

   

Consolidated Statement of Cash Flows

 

3

Notes to Consolidated Financial Statements

 

4

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

18

Item 3. Controls and Procedures

 

25

PART II. OTHER INFORMATION

 

26

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

 

26

Item 6. Exhibits

 

26

SIGNATURES

 

27

CERTIFICATIONS

   

Exhibit 10.9 Employment Agreement between the Company and Randall G. Smith, dated September 1, 2004

   

Exhibit 10.10 Employment Agreement between the Company and Ronald T. Linares, dated September 1, 2004

   

Exhibit 10.11 Amended and Restated Promissory Note between the Company and Cornelis F. Wit, dated June 30, 2004

   

Exhibit 10.12 Amended and Restated Promissory Note between the Company and Guus van Kesteren, dated June 30, 2004

   
Exhibit 31.1 Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act OF 2002– CEO Cornelis F. Wit    
Exhibit 31.2 Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act OF 2002– CFO Ronald T. Linares    
Exhibit 32.1 Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act OF 2002 – CEO Cornelis F. Wit    
Exhibit 32.2 Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act OF 2002 – CFO Ronald T. Linares    

 

2


Table of Contents

OMNICOMM SYSTEMS, INC.

CONSOLIDATED BALANCE SHEETS

 

    

September 30,

2004


    December 31,
2003


 
     (unaudited)        
ASSETS                 

CURRENT ASSETS

                

Cash

   $ 59,076     $ 1,977  

Accounts receivable

     69,723       112,026  

Prepaid expenses

     25,844       20,799  
    


 


Total current assets

     154,643       134,802  

PROPERTY AND EQUIPMENT, net

     56,879       139,830  

OTHER ASSETS

                

Other assets

     12,997       12,997  
    


 


TOTAL ASSETS

   $ 224,519     $ 287,629  
    


 


LIABILITIES AND SHAREHOLDERS’ EQUITY                 

CURRENT LIABILITIES

                

Accounts payable and accrued expenses

   $ 936,230     $ 854,150  

Accrued payroll taxes

     132,891       111,159  

10% Convertible Notes

     375,000       375,000  

Notes payable – current portion

     125,000       -0-  

Notes payable, related party – current portion

     6,000       -0-  

Deferred revenue

     299,360       416,592  
    


 


Total current liabilities

     1,874,481       1,756,901  

NOTES PAYABLE, net of current portion

     1,316,927       880,926  

NOTES PAYABLE RELATED PARTY, net of current portion

     848,742       551,644  
    


 


TOTAL LIABILITIES

     4,040,150       3,189,471  
    


 


COMMITMENTS AND CONTINGENCIES

                

SHAREHOLDERS’ EQUITY (DEFICIT)

                

Undesignated preferred stock - $.001 par value. 4,022,500 shares authorized, no shares issued and outstanding

     -0-       -0-  

Series B convertible preferred stock, - $.001 par value. 230,000 shares authorized, 103,750 and 157,500 issued and outstanding, respectively; liquidation preference $1,037,500 and $1,575,500, respectively

     104       158  

Series C convertible preferred stock, - $.001 par value. 747,500 shares authorized, 337,150 and 337,150 issued and outstanding, respectively; liquidation preference $3,371,500 and $3,371,500, respectively

     337       337  

5% Series A convertible preferred stock - $0.001 par value, 5,000,000 shares authorized; 4,215,224 and 4,215,224 issued and outstanding, respectively; liquidation preference $4,215,224 and $4,215,224, respectively

     4,215       4,215  

Common stock – 150,000,000 shares authorized, 22,679,277 and 17,929,277 issued and outstanding, after deducting 669,777 and 669,777 shares of treasury stock, at $.001 par value, respectively

     23,304       18,554  

Additional paid in capital – preferred

     8,240,948       8,778,394  

Additional paid in capital – common

     13,796,745       12,671,495  

Less: Treasury stock, cost method, 669,777 and 669,777 shares, respectively

     (299,861 )     (299,861 )

Accumulated deficit

     (25,581,423 )     (24,032,562 )

Deferred compensation

     -0-       (42,572 )
    


 


TOTAL SHAREHOLDERS’ EQUITY (DEFICIT)

     (3,815,631 )     (2,901,842 )
    


 


TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY (DEFICIT)

   $ 224,519     $ 287,629  
    


 


 

See accompanying summary of accounting policies and notes to financial statements.

 

1


Table of Contents

OMNICOMM SYSTEMS, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2004 AND SEPTEMBER 30, 2003

(Unaudited)

 

     For the nine months ended
September 30,


    For the three months ended
September 30,


 
     2004

    2003

    2004

    2003

 

Revenues

   $ 686,839     $ 539,549     $ 245,788     $ 205,999  

Cost of sales

     192,274       151,613       62,117       56,279  
    


 


 


 


Gross margin

     494,565       387,936       183,671       149,720  

Other expenses

                                

Salaries, benefits and related taxes

     1,343,308       1,301,348       428,700       384,405  

Rent & occupancy expenses

     114,593       108,455       38,811       33,173  

Consulting – medical advisory

     -0-       (53,385 )     -0-       -0-  

Consulting – marketing sales

     -0-       2,239       -0-       -0-  

Legal and professional fees

     142,726       92,594       46,894       61,077  

Travel

     44,540       33,756       8,794       4,899  

Telephone and internet

     50,883       49,755       17,121       14,337  

Selling, general and administrative

     89,648       97,106       17,068       29,643  

Interest expense, net

     149,696       90,232       60,796       31,810  

Depreciation and amortization

     108,032       109,157       35,940       35,455  
    


 


 


 


Total other expenses

     2,043,426       1,831,257       654,124       594,799  
    


 


 


 


(Loss) before taxes and preferred dividends

     (1,548,861 )     (1,443,321 )     (470,453 )     (445,079 )

Income tax expense (benefit)

     -0-       -0-       -0-       -0-  
    


 


 


 


Net income (loss)

     (1,548,861 )     (1,443,321 )     (470,453 )     (445,079 )

Preferred stock dividends in arrears Series A Preferred

     (154,162 )     (153,600 )     (51,762 )     (51,763 )

Preferred stock dividends in arrears Series B Preferred

     (77,334 )     (119,671 )     (24,123 )     (40,329 )

Preferred stock dividends in arrears Series C Preferred

     (202,474 )     (197,941 )     (67,984 )     (67,985 )

Preferred stock dividends – deemed dividends

     -0-       (409,919 )     -0-       (113,998 )
    


 


 


 


Total preferred stock dividends

     (433,970 )     (881,131 )     (143,869 )     (274,075 )
    


 


 


 


Net income (loss) attributable to common stockholders

   $ (1,982,831 )   $ (2,324,452 )   $ (614,322 )   $ (719,154 )
    


 


 


 


Net (loss) per share

   $ (0.10 )   $ (0.18 )   $ (0.03 )   $ (0.05 )
    


 


 


 


Weighted average number of shares outstanding

     19,883,109       12,928,214       21,198,842       13,911,951  
    


 


 


 


 

See accompanying summary of accounting policies and notes to financial statements

 

2


Table of Contents

OMNICOMM SYSTEMS, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2004 AND SEPTEMBER 30, 2003

(unaudited)

 

     2004

    2003

 

CASH FLOWS FROM OPERATING ACTIVITIES

                

Net income (loss)

   $ (1,548,861 )   $ (1,443,321 )

Adjustment to reconcile net income to net cash provided by (used in) operating activities:

                

Depreciation and amortization

     108,032       109,157  

Amortization of deferred compensation

     42,572       22,137  

Change in assets and liabilities:

                

Accounts receivable

     42,303       170,713  

Prepaid expenses

     (5,045 )     (12,717 )

Accounts payable and accrued expenses

     103,812       (110,717 )

Deferred revenue

     (117,232 )     47,458  
    


 


Net cash provided by (used in) operating activities

     (1,374,419 )     (1,217,290 )
    


 


CASH FLOWS FROM INVESTING ACTIVITIES

                

Purchase of property and equipment

     (25,081 )     (10,550 )
    


 


Net cash provided by (used in) investing activities

     (25,081 )     (10,550 )
    


 


CASH FLOWS FROM FINANCING ACTIVITIES

                

Proceeds from notes payable

     864,099       218,600  

Proceeds from the issuance of common stock, net of issuance costs

     592,500       567,000  

Payments on notes payable

     -0-       (2,600 )

Issuance of Series C convertible preferred stock, net of issuance costs

     -0-       265,265  
    


 


Net cash provided by (used in) financing activities

     1,456,599       1,048,265  
    


 


Net increase (decrease) in cash and cash equivalents

     57,099       (179,575 )

Cash and cash equivalents at beginning of period

     1,977       194,677  
    


 


Cash and cash equivalents at end of period

   $ 59,076     $ 15,102  
    


 


 

     For the nine months ended
September 30,


     2004

   2003

Supplemental Disclosure of Cash Flow Information:

             

Cash paid during the period for:

             

Income tax

   $ -0-    $ -0-
    

  

Interest

   $ -0-    $ -0-
    

  

Non-cash Transactions

             

Conversion of Series B Preferred Stock into shares of common stock

   $ 538,000    $ -0-

Treasury stock repurchase of common stock for trade receivable

   $ -0-    $ 1,067

 

See accompanying summary of accounting policies and notes to financial statements

 

3


Table of Contents

OMNICOMM SYSTEMS, INC.

NOTES TO THE CONSOLIDATED INTERIM FINANCIAL STATEMENTS

September 30, 2004

(unaudited)

 

NOTE 1: ORGANIZATION AND NATURE OF OPERATIONS

 

OmniComm Systems, Inc. is a healthcare technology company that provides Internet-based electronic data capture (“EDC”) solutions and related value-added services to pharmaceutical and biotech companies, clinical research organizations, and other clinical trial sponsors. TrialMaster® allows clinical trial sponsors and investigative sites to securely collect, validate, transmit, and analyze clinical trial data. The Medical Event Reporting System (MERS-TH) is an event reporting system that is being developed for hospitals and medical centers to collect, classify, and analyze events that could potentially compromise patient safety. MERS-TH provides the opportunity to study and monitor both actual and near-miss events to facilitate process improvement efforts. MERS-TH is being developed in conjunction with Columbia University and will be marketed by both of us to hospital and medical centers in the U.S. and Europe.

 

NOTE 2: SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

BASIS OF PRESENTATION AND PRINCIPLES OF CONSOLIDATION

 

The Company’s accounts include those of its two wholly owned subsidiaries, OmniCommerce and OmniTrial B.V and have been prepared in conformity with (i) generally accepted accounting principles; and (ii) the rules and regulations of the United States Securities and Exchange Commission. All significant intercompany accounts and transactions between the Company and its subsidiaries have been eliminated in consolidation.

 

ESTIMATES IN FINANCIAL STATEMENTS

 

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and footnotes thereto. Actual results may differ from those estimates.

 

RECLASSIFICATIONS

 

Certain reclassifications have been made in the 2003 financial statements to conform to the 2004 presentation. These reclassifications did not have any effect on net income (loss) or shareholders’ equity.

 

SEGMENT INFORMATION

 

The Company operates in one reportable segment.

 

CASH AND CASH EQUIVALENTS

 

Cash equivalents consist of highly liquid, short-term investments with maturities of 90 days or less. The carrying amount reported in the accompanying balance sheets approximates fair value.

 

ACCOUNTS RECEIVABLE

 

Accounts receivable are judged as to collectibility by management and an allowance for bad debts is established as necessary. As of each balance sheet date, no reserve was considered necessary.

 

4


Table of Contents

OMNICOMM SYSTEMS, INC.

NOTES TO THE CONSOLIDATED INTERIM FINANCIAL STATEMENTS

SEPTEMBER 30, 2004

(unaudited)

(continued)

 

CONCENTRATION OF CREDIT RISK

 

Accounts receivable subject the Company to its highest potential concentration of credit risk. The Company reserves for credit losses based on historical losses and performs on-going evaluations of its receivables and clients. To date the Company has not incurred any losses from receivables related to TrialMaster sales. The Company does not require collateral on trade accounts receivables.

 

PROPERTY AND EQUIPMENT

 

Property and equipment are recorded at cost. Additions and betterments are capitalized; maintenance and repairs are expensed as incurred. Depreciation is calculated using the straight-line method over the asset’s estimated useful life, which is 5 years for leasehold improvements, equipment and furniture and 3 years for software. Gains or losses on disposal are charged to operations.

 

INTANGIBLE AND OTHER ASSETS

 

Intangible assets are amortized on a straight-line basis over periods ranging from one to five years. The Company continually reviews the recoverability of the carrying value of these assets using the methodology prescribed in SFAS 121. The Company also reviews long-lived assets and the related intangible assets for impairment whenever events or changes in circumstances indicate the carrying amounts of such assets may not be recoverable. If it is determined the carrying amount of the assets is permanently impaired then intangible assets are written down to fair value and the useful life of the asset may be changed prospectively. Fair value is determined based on discounted cash flows, appraised values or management’s estimates, depending upon the nature of the assets. As of September 30, 2004, management believes no revision to the remaining useful lives or write-down of intangible assets is required.

 

DEFERRED REVENUE

 

Deferred revenue represents cash advances received in excess of revenue earned on on-going contracts. Payment terms vary with each contract but may include an initial payment at the time the contract is executed, with future payments dependent upon the completion of certain contract phases or targeted milestones. In the event of contract cancellation, the Company is entitled to payment for all work performed through the point of cancellation. As of September 30, 2004, the Company had $299,360 in deferred revenues relating to contracts for services to be performed over periods ranging from 1 month to approximately 5 years.

 

REVENUE RECOGNITION POLICY

 

OmniComm’s revenue model is transaction-based and can be implemented either as an ASP (application service provider) or licensed for implementation by a customer such as a pharmaceutical company. Revenues are derived from the set-up of clinical trial engagements; on-going maintenance fees incurred throughout the duration of an engagement; fees for report writing and change orders. The clinical trials that are conducted using TrialMaster can last from a few months to several years. Most of the fees associated with our product including post-setup customer support in the form of maintenance charges are recognized ratably over the term of the clinical trial. Cost of sales is primarily comprised of programmer salaries and payroll taxes and is expensed as incurred.

 

5


Table of Contents

OMNICOMM SYSTEMS, INC.

NOTES TO THE CONSOLIDATED INTERIM FINANCIAL STATEMENTS

SEPTEMBER 30, 2004

(unaudited)

(continued)

 

The Company recognizes revenues, for both financial statement and tax purposes in accordance with SEC Staff Accounting Bulletin No. 104 “Revenue Recognition (SAB 104)”. SAB 104 requires that revenues be recognized ratably over the life of a contract. In accordance with SAB 104 the Company will periodically record deferred revenues relating to advance payments in contracts. As of September 30, 2004, the Company had $299,360 in deferred revenue relating to contracts for services to be performed over periods ranging from 1 month to approximately 5 years.

 

ADVERTISING

 

Advertising costs are expensed as incurred. Advertising costs were $(680) and $3,301 for the nine months ended September 30, 2004 and 2003, respectively.

 

RESEARCH AND DEVELOPMENT EXPENSES

 

Software development costs are included in research and development and are expensed as incurred. Statement of Financial Accounting Standards No. 86 (“SFAS 86”) requires the capitalization of certain development costs of software to be sold once technological feasibility is established, which the Company defines as completion to the point of marketability. The capitalized cost is then amortized on a straight-line basis over the estimated product life. To date, the period between achieving technological feasibility and the general availability of such software has been short and software development costs qualifying for capitalization have been immaterial. Accordingly, the Company has not capitalized any software development costs under SFAS 86. Research and development expense was approximately $393,946 in 2004 and $401,034 in 2003 for the nine months ended September 30, respectively.

 

STOCK BASED COMPENSATION

 

Stock-based compensation is recognized using the intrinsic value method in accordance with the provisions of Accounting Principles Board Opinion No. 25, “Accounting for Stock Issued to Employees” and, accordingly, does not recognize compensation expense for its stock-based awards to employees in the Consolidated Statements of Income. For disclosure purposes, pro forma net loss and loss per common share are provided in accordance with Statement of Financial Accounting Standards No. 123, “Accounting for Stock Based Compensation”, as if the fair value method had been applied. See Note 12 for pro forma information on the impact of the fair-value method of accounting for stock options.

 

EARNINGS PER SHARE

 

The Financial Accounting Standards Board issued Statement of Financial Accounting Standards (“SFAS”) No. 128, “Earnings per Share.” SFAS 128 replaced the previously reported primary and fully diluted earnings per share with basic and diluted earnings per share. Unlike primary earnings per share, basic earnings per share excludes any dilutive effects of options, warrants, and convertible securities. The diluted earnings per share calculation is very similar to the previously utilized fully diluted earnings per share calculation method.

 

6


Table of Contents

OMNICOMM SYSTEMS, INC.

NOTES TO THE CONSOLIDATED INTERIM FINANCIAL STATEMENTS

SEPTEMBER 30, 2004

(unaudited)

(continued)

 

Basic earnings per share were calculated using the weighted average number of shares outstanding of 19,883,109 and 12,928,214 for the nine months ended September 30, 2004 and 2003, respectively and 21,198,842 and 13,911,951 for the three months ended September 30, 2004 and 2003, respectively. There were no differences between basic and diluted earnings per share. Options to purchase 3,687,770 shares of common stock at prices ranging from $.15 to $2.75 per share were outstanding at September 30, 2004. Stock warrants to purchase 16,751,296 shares of common stock at prices ranging from $0.25 to $10.00 per share were outstanding at September 30 2004. The Company granted a Unit Purchase Option (“Agent Option”) to the Placement Agent of its Series B Convertible Preferred Stock that provides the Placement Agent the ability to purchase 27,000 Series B Preferred Shares with 1,080,000 detachable common stock warrants. The exercise of the Agent Option would result in the issuance of an aggregate of 2,160,000 shares of common stock at an exercise price of $0.25 per share. The options, warrants and Agent Options were not included in the computation of diluted earnings per share because they have an anti-dilutive effect on net loss per share. The Company’s convertible debt and convertible preferred stock have an anti-dilutive effect on net loss per share.

 

The Company granted a Unit Purchase Option (“Agent Option”) to the Placement Agent of its Series C Convertible Preferred Stock that provides the Placement Agent the ability to purchase 24,848 Series C Preferred Shares with 496,950 detachable common stock warrants. The exercise of the Agent Option would result in the issuance of an aggregate of 1,490,850 shares of common stock at an exercise price of $0.25 per share. The warrants and Agent Options were not included in the computation of diluted earnings per share because they have an anti-dilutive effect on net loss per share.

 

INCOME TAXES

 

The Company accounts for income taxes in accordance with Statement of Financial Accounting Standards No. 109, “Accounting for Income Taxes.” SFAS 109 has as its basic objective the recognition of current and deferred income tax assets and liabilities based upon all events that have been recognized in the financial statements as measured by the provisions of the enacted tax laws.

 

Valuation allowances are established when necessary to reduce deferred tax assets to the estimated amount to be realized. Income tax expense represents the tax payable for the current period and the change during the period in the deferred tax assets and liabilities.

 

IMPACT OF NEW ACCOUNTING STANDARDS

 

In March 2004, the Financial Accounting Standards Board (“FASB”) issued an exposure draft of Proposed Statement of Financial Accounting Standards, “Share-Based Payment”, an amendment of FASB Statement No. 123. This proposed Statement addresses the accounting for transactions in which an enterprise exchanges its equity instruments for employee services. It also addresses transactions in which an enterprise incurs liabilities that are based on the fair value of the enterprise’s equity instruments or that may be settled by the issuance of those equity instruments in exchange for employee services. For public entities, the cost of employee services received in exchange for equity instruments, including employee stock options, would be measured based on the grant-date fair value of those instruments. That cost would be recognized as compensation expense over the service period, which would normally be the vesting period.

 

7


Table of Contents

OMNICOMM SYSTEMS, INC.

NOTES TO THE CONSOLIDATED INTERIM FINANCIAL STATEMENTS

SEPTEMBER 30, 2004

(unaudited)

(continued)

 

If the proposed statement were adopted by us as currently proposed, it would require that compensation expense be recorded for employee stock options vesting or granted subsequent to May 31, 2005. The ultimate impact on diluted earnings per share of expensing stock options will be dependent upon the final pronouncement issued by the FASB, the method to be used for valuation of stock options determined by us and the amount of future stock option grants.

 

In March 2004, the FASB issued Proposed FASB Staff Position No. FAS 106-b (“FAS 106-b”) “Accounting and Disclosure Requirements Related to the Medicare Prescription Drug, Improvement and Modernization Act of 2003.” FAS 106-b provides guidance on the accounting for the effects of the Medicare Prescription Drug, Improvement and Modernization Act of 2003 for employers that sponsor post-retirement health care plans that provide prescription drug benefits. FAS 106-b will not have a material effect on us since we do not offer prescription drug benefits to any retirees at September 30, 2004.

 

NOTE 3: OPERATIONS AND LIQUIDITY

 

We have experienced negative cash flow from operations since 1999 and have funded our activities to date primarily from debt and equity financings. We will continue to require substantial funds to continue our research and development activities and to market, sell and commercialize our technology. We will need to raise substantial additional capital to fund our future operations. Our capital requirements will depend on many factors, including the problems, delays, expenses and complications frequently encountered by companies developing and commercializing new technologies; the progress of our research and development activities; the rate of technological advances; determinations as to the commercial potential of our technology under development; the status of competitive technology; the establishment of collaborative relationships; the success of our sales and marketing programs; and other changes in economic, regulatory or competitive conditions in our planned business.

 

Estimates about the adequacy of funding for our activities are based upon certain assumptions, including assumptions that the research and development programs relating to our technology can be conducted at projected costs and that progress towards the commercialization of our technology will be timely and successful. There can be no assurance that changes in our research and development plans, acquisitions or other events will not result in accelerated or unexpected expenditures.

 

To satisfy our capital requirements, we may seek additional financing through debt and equity financings. There can be no assurance that any such funding will be available to us on favorable terms or at all. If adequate funds are not available when needed, we may be required to delay, scale back or eliminate some or all of our research and product development and marketing programs. If we are successful in obtaining additional financings, the terms of such financings may have the effect of diluting or adversely affecting the holdings or the rights of the holders of our common and preferred stock.

 

The ability of the Company to continue in existence is dependent on its having sufficient financial resources to bring products and services to market for marketplace acceptance. As a result of its significant losses, negative cash flows from operations, and accumulated deficits for the periods ending September 30, 2004 there is doubt about the Company’s ability to continue as a going concern.

 

8


Table of Contents

OMNICOMM SYSTEMS, INC.

NOTES TO THE CONSOLIDATED INTERIM FINANCIAL STATEMENTS

SEPTEMBER 30, 2004

(unaudited)

(continued)

 

NOTE 4: PROPERTY AND EQUIPMENT, AT COST

 

Property and equipment consists of the following:

 

     September 30, 2004

   December 31, 2003

    
     Cost

   Accumulated
Depreciation


   Cost

   Accumulated
Depreciation


   Estimated
Useful Lives


Computer and office equipment

   $ 443,960    $ 402,639    $ 423,177    $ 337,604    5 years

Leasehold improvements

     3,299      2,547      3,299      2,052    5 years

Computer software

     274,167      269,755      269,869      235,196    3 years

Office furniture

     52,950      42,556      52,950      34,613    5 years
    

  

  

  

    
     $ 774,376    $ 717,497    $ 749,295    $ 609,465     
    

  

  

  

    

 

Depreciation expense for the nine months ended September 30, 2004 and 2003 was $108,032 and $109,157 respectively.

 

NOTE 5: ACCOUNTS PAYABLE AND ACCRUED EXPENSES

 

Accounts payable and accrued expenses consist of the following at September 30, 2004 and December 31, 2003:

 

     09/30/04

   12/31/03

Accounts payable

   $ 351,835    $ 255,890

Accrued payroll and related costs

     59,260      15,479

Other accrued expenses

     206,427      236,927

Accrued interest

     191,189      218,335

Accrued expenses of OmniTrial BV

     127,519      127,519
    

  

Total accounts payable and accrued expenses

   $ 936,230    $ 854,150
    

  

 

Other accrued expenses consist primarily of placement agent fees and expenses due on private placements of our debt and equity securities that occurred during 2001 to 2004 and accrued legal fees associated with the sale of Series C Convertible Preferred Stock.

 

NOTE 6: EARNINGS PER SHARE

 

Basic earnings per shares (“EPS”) is computed by dividing income available to common shareholders (which for the Company equals its net loss) by the weighted average number of common shares outstanding, and dilutive EPS adds the dilutive effect of stock options and other common stock equivalents. Antidilutive shares aggregating 44,836,065 have been omitted from the calculation of dilutive EPS for the nine months ended September 30, 2004. A reconciliation between numerators and denominators of the basic and diluted earnings per shares is as follows:

 

     The Nine Months Ended September 30, 2004

    The Nine Months Ended September 30, 2003

 
     Income
Numerator


    Shares
Denominator


   Per-Share
Amount


    Income
Numerator


    Shares
Denominator


   Per-Share
Amount


 

Basic EPS

   $ (1,982,831 )   19,883,109    $ (0.10 )   $ (2,324,452 )   12,928,214    $ (0.18 )

Effect of Dilutive Securities None.

     -0-     -0-      -0-       -0-     -0-      -0-  
    


 
  


 


 
  


Diluted EPS

   $ (1,982,831 )   19,883,109    $ (0.10 )   $ (2,324,452 )   12,928,214    $ (0.18 )

 

9


Table of Contents

OMNICOMM SYSTEMS, INC.

NOTES TO THE CONSOLIDATED INTERIM FINANCIAL STATEMENTS

SEPTEMBER 30, 2004

(unaudited)

(continued)

 

     The Three Months Ended
September 30, 2004


    The Three Months Ended September 30, 2003

 
     Income
Numerator


    Shares
Denominator


   Per-Share
Amount


    Income
Numerator


    Shares
Denominator


   Per-Share
Amount


 

Basic EPS

   $ (614,322 )   21,198,842    $ (0.03 )   $ (719,154 )   13,911,951    $ (0.05 )

Effect of Dilutive Securities None.

     -0-     -0-      -0-       -0-     -0-      -0-  
    


 
  


 


 
  


Diluted EPS

   $ (614,322 )   21,198,842    $ (0.03 )   $ (719,154 )   13,911,951    $ (0.05 )

 

NOTE 7: NOTES PAYBLE

 

At September 30 2004, the Company owed $2,296,669 in notes payable. The table below provides details as to the terms and conditions of the notes payable.

 

Note Holder


   Origination
Date


  

Due

Date


   Interest
Rate


    Amount

   Short
Term


  

Long

Term


Guus van Kesteren

   6/30/2004    10/31/2006    9.0 %   $ 364,758    $ 0    $ 364,758

Magnolia Private Fnd.

   6/30/2004    10/31/2006    9.0 %     596,052      0      596,052

Nico Letschert

   7/31/2002    10/31/2005    9.0 %     10,000      0      10,000

Nico Letschert

   9/3/2002    10/31/2005    9.0 %     10,000      0      10,000

Randall Smith

   11/25/2002    1/31/2005    9.0 %     6,000      6,000      0

Cornelis Wit

   6/30/2004    10/31/2006    9.0 %     483,984      0      483,984

Guy Brissette

   12/30/2002    1/31/2005    9.0 %     100,000      100,000      0

Noesis Capital

   6/30/2004    10/31/2006    9.0 %     450,875      0      450,875

Carel Letschert

   11/7/2003    1/31/2005    9.0 %     25,000      25,000      0

Noesis NV

   1/30/2004    1/31/2006    9.0 %     100,000      0      100,000

Noesis NV

   6/17/2004    1/31/2006    9.0 %     50,000      0      50,000

Wim Letschert

   6/30/2004    1/31/2006    9.0 %     50,000      0      50,000

Carel Letschert

   7/29/2004    10/31/2006    9.0 %     50,000      0      50,000
                    

  

  

                     $ 2,296,669    $ 131,000    $ 2,165,669
                    

  

  

 

NOTE 8: CONVERTIBLE NOTES

 

During the first quarter of 1999, the Company issued 10% Convertible Notes Payable in the amount of $862,500 pursuant to a Confidential Private Placement Memorandum. There were costs of $119,625 associated with this offering. The Company also granted the agent the option to purchase 250,000 common shares at $.001 per share. The agent exercised the option. The net proceeds to the Company were $742,875. The notes bear interest at ten percent annually, payable semi-annually. The notes are convertible after maturity, which is five years, into shares of common stock of the Company at $1.25 per share. As of September 30, 2004 approximately $487,500 of the Convertible Notes had been converted into 390,000 shares of common stock of the Company leaving an outstanding principal balance of $375,000.

 

10


Table of Contents

OMNICOMM SYSTEMS, INC.

NOTES TO THE CONSOLIDATED INTERIM FINANCIAL STATEMENTS

SEPTEMBER 30, 2004

(unaudited)

(continued)

 

The Company is currently in default on principal and interest payments owed totaling $514,735 on its 10% Convertible Notes. The terms of the notes provide a payment grace period of thirty days in which to make required semi-annual interest payments. The company has been in default since January 30, 2002. At the option of the note holders the full amount of the convertible notes could be declared in default.

 

NOTE 9: COMMITMENTS AND CONTINGENCIES

 

The Company currently leases office space under an operating lease. The minimum future lease payments required under the Company’s operating leases at September 30, 2004 are as follows:

 

2004

   $ 22,629

2005

     54,522

2006

     0

2007

     0

2008

     0
    

Total

   $ 77,151
    

 

In addition, to annual base rental payments, the Company pays for the operating expenses associated with its leased office space and is responsible for any escalation in operating expenses as determined in the lease. Rental expense was $114,593 and $108,455 for the nine months ended September 30, 2004 and 2003.

 

EMPLOYMENT AGREEMENTS

 

In August 2003, we entered into an employment agreement with Cornelis F. Wit to serve as our Chief Executive Officer and President through December 31, 2004. Mr. Wit receives an annual salary of $175,000 payable in cash and/or stock plus a bonus tied to our operating results. As part of the agreement incentive options are awardable under the agreement based upon sales and cash flow objectives. In the event that the we consummate a transaction with a third party resulting in the sale, merger, consolidation, reorganization or other business combination involving all or a majority of our business, assets or stock, whether effected in one transaction or a series of transactions due to the initiative of Mr. Wit (whether or not during the term of the agreement), Mr. Wit will receive a fee equal to 2% of the aggregate consideration. The agreement also provides, among other things, for participation in employee benefits available to employees and executives. Under the terms of the agreement, we may terminate Mr. Wit’s employment upon 30 days notice of a material breach and Mr. Wit may terminate the agreement under the same terms and conditions. The employment agreement contains customary non-disclosure provisions, as well as a one year non-compete clause if Mr. Wit leaves the company voluntarily or a six month non-compete clause following his termination by us.

 

In September 2004, we entered into a one-year employment agreement with Mr. Randall Smith to serve as our Chief Technology Officer. Under the terms of the agreement, as compensation for his services, Mr. Smith receives an annual salary of $181,500 to be paid in the form of cash and/or stock, as agreed upon by the parties, and he is eligible to receive a bonus based upon achieving technology related milestones. The agreement also provides, among other things, for participation in employee benefit plans or programs applicable to employees and executives. Under the terms of the agreement, we may terminate the employment of Mr. Smith upon 30 days notice of a material breach and Mr. Smith may terminate the agreement under the same terms and conditions.

 

11


Table of Contents

OMNICOMM SYSTEMS, INC.

NOTES TO THE CONSOLIDATED INTERIM FINANCIAL STATEMENTS

SEPTEMBER 30, 2004

(unaudited)

(continued)

 

If Mr. Smith is terminated by us for any reason other than for cause, we must pay him severance benefits equal to six months salary. The employment agreement contains customary non-disclosure provisions, as well as a one year non-competition restriction following the termination of the agreement. The agreement renews automatically for one-year terms unless expressly cancelled by either Mr. Smith or the Company in writing ninety (90) days prior to termination of the term.

 

In September 2004, we entered into a one-year employment agreement with Mr. Ronald Linares to serve as our Chief Financial Officer. Under the terms of this agreement, Mr. Linares receives an annual salary of $161,500 to be paid in the form of cash and/or stock, as agreed upon by the parties, and he is eligible to receive additional incentive compensation based upon achieving financial milestones. The agreement also provides, among other things, for participation in employee benefit plans or programs applicable to employees and executives. Under the terms of the agreement, we may terminate the employment of Mr. Linares upon 30 days notice of a material breach and Mr. Linares may terminate the agreement under the same terms and conditions. If Mr. Linares is terminated by us for any reason other than for cause, we must pay him severance benefits equal to six months salary. The employment agreement contains customary non-disclosure provisions, as well as a one year non-competition restriction following the termination of the agreement. The agreement renews automatically for one-year terms unless expressly cancelled by either Mr. Linares or the Company in writing ninety (90) days prior to termination of the term.

 

In January 2003, we entered into a three-year employment agreement with Mr. Charles Beardsley to serve as our Senior Vice President for Sales and Marketing. Under the terms of this agreement, Mr. Beardsley currently receives an annual salary of $165,000 to be paid in the form of cash and/or stock, as agreed upon by the parties, and he is eligible to receive additional incentive compensation based upon achieving financial milestones. Mr. Beardsley is eligible for a commission, payable on a quarterly basis, equal to 2% of the Company’s Net Operating Income as defined in an exhibit to his employment contract. Mr. Beardsley was granted an aggregate of 150,000 options under our 1998 Stock Incentive Plan. The options, which vest 50,000 annually beginning with January 2, 2004, are exercisable at a price of $0.25 per share, for five years from the date of vesting. Mr. Beardsley received a grant of 100,000 shares of restricted common stock upon execution of his employment agreement. The agreement also provides, among other things, for participation in employee benefit plans or programs applicable to employees and executives. Under the terms of the agreement, we may terminate the employment of Mr. Beardsley upon 30 days notice of a material breach and Mr. Beardsley may terminate the agreement under the same terms and conditions. If Mr. Beardsley is terminated by us for any reason other than for cause, we must pay him severance benefits equal to twelve months salary. The employment agreement contains customary non-disclosure provisions.

 

FINANCIAL ADVISORY AGREEMENT

 

During March 2002, the Company entered into a one-year financial advisory agreement with Noesis Capital to assist the Company in performing certain financial advisory services including the sale of securities, and the possible sale, merger or other business combination involving the Company. Pursuant to this agreement, the Company is obligated to pay $90,000 in professional fees during the one-year term of the agreement. The advisory agreement was extended on May 11, 2004 for a term that will expire on December 31, 2005.

 

12


Table of Contents

OMNICOMM SYSTEMS, INC.

NOTES TO THE CONSOLIDATED INTERIM FINANCIAL STATEMENTS

SEPTEMBER 30, 2004

(unaudited)

(continued)

 

NOTE 10: RELATED PARTY TRANSACTIONS

 

Cornelis F. Wit, our President and Chief Executive Officer and a member of our board of directors served as President of Corporate Finance of Noesis Capital Corp. from March 1995 to September 2000. Noesis Capital Corp., a NASD member firm, has served as placement agent for us in six private placements of securities which occurred between September 1999 and September 2004. Guus van Kesteren, a member of our board of directors, is a consultant to Noesis Capital Corp.

 

Between February 2001 and July 2001, we borrowed an aggregate of $190,000 from Guus van Kesteren under promissory notes which bore interest of 12% per annum. These promissory notes were amended and restated on August 30, 2001 in the amount of $196,644 with new terms which included an interest rate of 8% per annum, and with one half of the principal payable upon the closing of any financing by us resulting in gross proceeds in excess of $2,000,000, and the balance of the principal together with accrued interest payable no later than August 30, 2003. This note was amended in September 2004 extending the maturity date to October 2006.

 

During March 2002, we borrowed $2,341 from Randall G. Smith, our Chairman of the board and Chief Technology Officer. This amount was repaid without interest on April 12, 2002. In addition, we borrowed $6,000 without interest from Mr. Smith on November 25, 2002. In March 2003 this note was amended and restated extending the maturity date to January 31, 2005.

 

In December 2002, we borrowed $50,000 from Cornelis Wit, our President and Chief Executive Officer and a member of our board of directors. This amount was borrowed under a promissory note bearing interest at a rate of 9% per annum, payable on March 31, 2003. This note was amended in September 2004 extending the maturity date to October 31, 2006.

 

In December 2002, we borrowed $50,000 from Guus van Kesteren a member of our board of directors. This amount was borrowed under a promissory note bearing interest at a rate of 9% per annum, payable on March 31, 2003. This note was amended in September 2004 extending the maturity date to October 31, 2006.

 

In March 2003, we borrowed $2,600 from Cornelis Wit, our Chief Executive Officer and President and a member of our board of directors. This amount was repaid without interest on April 3, 2003.

 

From September to November 2003 we borrowed $262,000 from Cornelis Wit, our President and Chief Executive Officer, and a member of our board of directors. These amounts were borrowed under promissory notes bearing interest at 9% per annum with maturity dates ranging from January 31, 2005 to October 31, 2005. These notes were amended and restated on September 30, 2004 under the terms of a new note bearing interest at 9% interest payable on October 31, 2006.

 

During October 2003, the Company borrowed $16,000 from Guus van Kesteren, a Company Director. This amount was borrowed under a promissory note bearing interest at a rate of 9% per annum, payable on October 31, 2005. On December 31, 2003, Mr. van Kesteren elected to convert this note payable into common stock of the Company at a conversion price of $0.25 per share. The Company issued 64,000 shares of restricted common stock in connection with this conversion.

 

13


Table of Contents

OMNICOMM SYSTEMS, INC.

NOTES TO THE CONSOLIDATED INTERIM FINANCIAL STATEMENTS

SEPTEMBER 30, 2004

(unaudited)

(continued)

 

From February to June 2004, the Company borrowed $106,000 from Guus van Kesteren, a Company Director. These amounts were borrowed under promissory notes bearing interest at 9% per annum with maturity dates ranging from January 31, 2006 to October 31, 2006. These notes were amended and restated on June 30, 2004 under the terms of a new note bearing interest at 9% interest payable on October 31, 2006.

 

From January to June 2004, the Company borrowed $153,500 from Cornelis Wit, the Company’s President and Chief Executive Officer and a Director. These amounts were borrowed under promissory notes bearing interest at 9% per annum with maturity dates ranging from January 31, 2006 to October 31, 2006. These notes were amended and restated on June 30, 2004 under the terms of a new note bearing interest at 9% interest payable on October 31, 2006.

 

NOTE 11: POST-RETIREMENT EMPLOYEE BENEFITS

 

The Company does not have a policy to cover employees for any health care or other welfare benefits that are incurred after employment (post-retirement). Therefore, no provision is required under SFAS’s 106 or 112.

 

NOTE 12: STOCKHOLDERS’ EQUITY (DEFICIT)

 

Our authorized capital stock consists of 150,000,000 shares of common stock, $.001 par value per share, and 10,000,000 shares of preferred stock, par value $.001 per share, of which 5,000,000 shares have been designated as 5% Series A Preferred, 230,000 shares have been designated as Series B Preferred Stock and 747,500 shares have been designated as Series C Preferred Stock.

 

As of September 30, 2004 we had the following outstanding securities:

 

  22,679,277 shares of common stock issued and outstanding;

 

  16,751,296 warrants issued and outstanding to purchase shares of our common stock;

 

  4,215,224 shares of our Series A Preferred Stock issued and outstanding, convertible into 2,810,149 shares of common stock

 

  103,750 shares of our Series B Preferred Stock issued and outstanding; convertible into 4,150,000 shares of common stock

 

  337,150 shares of our Series C Preferred Stock issued and outstanding; convertible into 13,486,000 shares of common stock

 

  a Series B Placement Agent Unit Option;

 

  a Series C Placement Agent Unit Option; and

 

  10% Convertible Notes, convertible into 300,000 shares of common stock

 

Preferred Stock Arrearges

 

There were arrearages of $444,484 and $290,322 on the Series A Preferred Stock for undeclared dividends as of September 30, 2004 and December 31, 2003.

 

There were arrearages of $443,264 and $365,930 on the Series B Preferred Stock for undeclared dividends as of September 30, 2004 and December 31, 2003.

 

14


Table of Contents

OMNICOMM SYSTEMS, INC.

NOTES TO THE CONSOLIDATED INTERIM FINANCIAL STATEMENTS

SEPTEMBER 30, 2004

(unaudited)

(continued)

 

There were arrearages of $525,204 and $322,730 on the Series C Preferred Stock for undeclared dividends as of September 30, 2004 and December 31, 2003.

 

Stock Option Plan

 

In 1998, the Company’s Board of Directors approved the OmniComm Systems 1998 Stock Option Plan, (the “1998 Plan”). The 1998 Plan provides for granting Incentive Stock Options, Nonqualified Stock Options, Stock Appreciation Rights, Restricted Stock Awards, Phantom Stock Unit Awards and Performance Share Units. Pursuant to the 1998 Plan the Company may grant options to purchase up to 5,000,000 shares of the Company’s common stock. The term of each option may not exceed ten years from the date of grant, and options vest in accordance with a vesting schedule established by the Plan administrator.

 

The Company’s share option activity and related information is summarized below:

 

     Nine months ended
September 30, 2004


  

Year ended

December 31, 2003


     Options

   Weighted
Average
Exercise
Price


   Options

   Weighted
Average
Exercise
Price


Outstanding at beginning of period

   3,593,500    $ 0.83    2,785,039    $ 1.00

Granted

   317,270    $ 0.25    1,471,000    $ 0.25

Exercised

   -0-    $ 0.00    40,000    $ 0.25

Cancelled

   223,000    $ 0.29    622,539    $ 0.27
    
         
  

Outstanding at end of period

   3,687,770    $ 0.68    3,593,500    $ 0.83
    
  

  
  

Exercisable at end of period

   3,203,270    $ 0.57    3,099,500    $ 0.53
    
  

  
  

 

The following table summarizes information about stock options outstanding at September 30, 2004:

 

     Outstanding

   Exercisable

Range of

Exercise Prices


   Number of
Options


   Weighted
Average
Remaining
Years of
Contractual
Life


   Weighted
Average
Exercise
Price


   Number of
Options


   Weighted
Average
Exercise
Price


$0.25 - $0.47

   3,102,770    3.87    $ 0.30    2,618,770    $ 0.31

$0.50 - $0.80

   257,000    5.51    $ 0.54    257,000    $ 0.54

$1.00 - $2.75

   328,000    0.87    $ 2.09    328,000    $ 2.09

 

Accounting for Stock Based Compensation

 

At September 30, 2004, the Company has one stock-based compensation plan which is described more fully above. The Company accounts for its plan under the recognition and measurement principles of APB Opinion No 25, “ Accounting for Stock Issued to Employees ”, (“APB 25”) and related interpretations. No stock-based employee compensation cost is reflected in net income, as all options granted under the plan had an exercise price equal to or above the market value of the underlying common stock on the date of grant. The following table illustrates the effect on net income and earnings per share if the company had applied the fair value recognition provisions of FASB Statement No. 123, “ Accounting for Stock-Based Compensation” to stock-based employee compensation.

 

15


Table of Contents

OMNICOMM SYSTEMS, INC.

NOTES TO THE CONSOLIDATED INTERIM FINANCIAL STATEMENTS

SEPTEMBER 30, 2004

(unaudited)

(continued)

 

     Nine months Ended
September 30,


 

(in thousands, except for per share data)


   2004

    2003

 

Net loss available to common stockholders As reported

   $ (1,983 )   $ (2,324 )

Deduct: Total stock-based employee compensation expense determined under fair value based method for all awards, net of related tax effects

     (9,688 )     (9,378 )
    


 


Pro forma net loss available to common stockholders

   $ (11,671 )   $ (11,702 )
    


 


Weighted average number of common shares outstanding used to compute net income (loss) per common share–basic and diluted

     19,883       12,928  
    


 


Basic and diluted net loss per share

                

As reported

   $ (0.10 )   $ (0.18 )
    


 


Pro forma

   $ (0.59 )   $ (0.91 )
    


 


 

The estimated fair value of each OmniComm option granted is calculated using the Black-Scholes pricing model. The weighted average assumptions used in the model were as follows:

 

     Nine months Ended
September 30,


 
     2004

    2003

 

Risk-free interest rate

   2.07 %   5.00 %

Expected years until exercise

   6 Years     6 Years  

Expected stock volatility

   115.0 %   150.0 %

Dividend yield

   0 %   0 %

 

Other Stock Based Compensation

 

During 2003, the Company issued an aggregate of 100,000 shares of restricted common stock to employees. The stock issued had a fair market value of $25,000 and was issued under the terms of an employment contract.

 

NOTE 13: INCOME TAXES

 

The tax expense (benefit) for income taxes differs from the amount computed by applying the statutory federal income tax rate of 34% to income (loss) before provision (benefit) for income taxes as follows:

 

     9/30/04

    9/30/03

 

Current tax expense (benefit):

                

Income tax at statutory rates

   $ -0-     $ -0-  
    


 


Deferred tax expense (benefit):

                

Amortization of goodwill and covenant

     -0-       -0-  

Operating loss carryforward

     (582,836 )     (543,122 )
    


 


       (582,836 )     (543,122 )
    


 


Valuation allowance

     582,836       543,122  
    


 


Total tax expense (benefit)

   $ -0-     $ -0-  
    


 


 

16


Table of Contents

OMNICOMM SYSTEMS, INC.

NOTES TO THE CONSOLIDATED INTERIM FINANCIAL STATEMENTS

SEPTEMBER 30, 2004

(unaudited)

(continued)

 

Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of our deferred tax assets and liabilities are as follows:

 

     9/30/04

    12/31/03

 

Deferred tax assets:

                

Amortization of intangibles

   $ 283,698     $ 283,698  

Operating loss carryforwards

     6,824,382       6,241,546  
    


 


Gross deferred tax assets

     7,108,080       6,525,244  
    


 


Valuation allowance

     (7,108,080 )     (6,525,244 )
    


 


Net deferred tax asset

   $ -0-     $ -0-  
    


 


 

The Company has net operating loss carryforwards (NOL) for income tax purposes of approximately $18,123,391. This loss is allowed to be offset against future income until the year 2023 when the NOL’s will expire. Other timing differences relate to depreciation and amortization for the stock acquisition of Education Navigator in 1998. The tax benefits relating to all timing differences have been fully reserved for in the valuation allowance account due to the lack of operating history and the substantial losses incurred through September 30, 2004.

 

NOTE 14: SUBSEQUENT EVENTS

 

The Company had a recorded liability of $132,891 at September 30, 2004 for federal employment taxes. The Company had fully satisfied the liability as of November 12, 2004.

 

17


Table of Contents

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OR PLAN OF OPERATIONS

 

General

 

The following information should be read in conjunction with the Consolidated Interim Financial Statements and Notes thereto and other information set forth in this report.

 

Forward-Looking Statements

 

Statements contained in this Form 10-QSB that are not historical fact are “forward looking statements”. These statements can often be identified by the use of forward-looking terminology such as “estimate”, “project”, “believe”, “expect”, “may”, “will”, “should”, “intends”, or “anticipates” or the negative thereof or other variations thereon or comparable terminology, or by discussions of strategy that involve risks and uncertainties. We wish to caution the reader that these forward-looking statements, such as statements relating to timing, costs and of the acquisition of, or investments in, existing business, the revenue or profitability levels of such businesses, and other matters contained in this Form 10-QSB regarding matters that are not historical facts, are only predictions. No assurance can be given that plans for the future will be consummated or that the future results indicated, whether expressed or implied, will be achieved. While sometimes presented with numerical specificity, these plans and projections and other forward-looking statements are based upon a variety of assumptions, which we consider reasonable, but which nevertheless may not be realized. Because of the number and range of the assumptions underlying our projections and forward-looking statements, many of which are subject to significant uncertainties and contingencies that are beyond our reasonable control, some of the assumptions inevitably will not materialize, and unanticipated events and circumstances may occur subsequent to the date of this Form 10-QSB. Therefore, our actual experience and results achieved during the period covered by any particular projections or forward-looking statements may differ substantially from those projected. Consequently, the inclusion of projections and other forward- looking statements should not be regarded as a representation by us or any other person that these plans will be consummated or that estimates and projections will be realized, and actual results may vary materially. There can be no assurance that any of these expectations will be realized or that any of the forward-looking statements contained herein will prove to be accurate. The Company does not undertake any obligation to update or revise any forward-looking statement made by it or on its behalf, whether as a result of new information, future events or otherwise.

 

Overview

 

We are a healthcare technology company that provides electronic data capture (“EDC”) solutions and related value-added services to pharmaceutical and biotechnology companies, clinical research organizations, and other clinical trial sponsors via our Web-based software, TrialMaster. TrialMaster allows clinical trial sponsors and investigative sites to securely collect, validate, transmit, and analyze clinical study data including patient histories, patient dosing, adverse events, and other clinical trial information. Medical Error Reporting System (“MERS-TH”) is being co-developed with Columbia University. MERS-TH has been designed to provide U.S. and European hospitals and medical centers, a standardized system for collecting data on medical errors, adverse events and near misses. All of our personnel are involved in the development and marketing of TrialMaster and MERS-TH.

 

The Nine months Ended September 30, 2004 Compared With the Nine months Ended September 30, 2003

 

Results of Operations

 

Revenues for the nine months ended September 30, 2004 were $686,839 compared to $539,549 for the same period in 2003, an increase of 27.3%. The revenue increase can be attributed to an incremental increase in per project revenue. We have found EDC users receptive to our products and believe our mix of technology and customer oriented design approach allow us to compete favorably. The combination of a flexible design architecture, robust features and competitive pricing of TrialMaster provide an attractive alternative to potential clients when compared to the products offered by our competitors.

 

18


Table of Contents

TrialMaster is currently being sold as an application service provider (“ASP”) that provides EDC and other services such as an enterprise management suite which assists its clients in the pharmaceutical, biotechnology and medical device industries in accelerating the completion of clinical trials. TrialMaster contracts provide for pricing that is based on both the size and duration of the clinical trial. Size parameters include the number of case report forms used to collect data and the number of sites utilizing TrialMaster. The client will pay a trial setup fee based on the previously mentioned factors, and then pay an on-going maintenance fee for the duration of the clinical trial that provides software, network and site support during the trial. Generally, these contracts will range in duration from four months to several years. Setup fees are generally earned prior to the inception of a trial, however, the revenues will be recognized in accordance with SEC Staff Accounting Bulletin No. 104 “Revenue Recognition” which requires that the revenues be recognized ratably over the life of the contract. The maintenance fee revenues are earned and recognized monthly. Costs associated with contract revenues are recognized as incurred.

 

Cost of goods sold increased to $192,274 in 2004 compared to $151,613 in 2003. Cost of goods sold were approximately 28.0% of sales in 2004 compared to 28.1% in fiscal 2003. Salaries have increased during 2004 due to the addition of one additional programmer as part of our trial operations. We used the services of a third party vendor on a European clinical trial conducted during 2003-2004. Cost of goods sold relates primarily to salaries and related benefits associated with the programmers, developers and systems analysts producing clinical trials on behalf of our clients.

 

We expect to increase development programming labor costs on an absolute basis as our trial revenues increase. We expect labor costs to remain at approximately 25% of sales. TrialMaster V3.0, the latest release of our trial-building software has improved our ability to reduce trial production related costs since it automates many of the trial building functions that were manually performed in prior releases of our software. We expect the next release of TrialMaster, V4.0, to increase the efficiency of trial building operations by 20 to 25%. V4.0 is being designed using Microsoft’s .Net® framework. Microsoft® .NET is described by Microsoft as a set of software technologies for connecting information, people, systems, and devices. This new generation of technology is based on Web services—small building-block applications that can connect to each other as well as to other, larger applications over the Internet.

 

Salaries and related expenses are our biggest expense at 65.7% of total Other Expenses for the first nine months of 2004. Salaries and related expenses totaled $1,343,308 in 2004 compared to $1,301,348 in 2003, an increase of 3.2%. We currently employ approximately 16 employees out of our Davie, Florida corporate office and have two out-of-state employees. We expect to increase headcount by about 25% within our production function in concert with anticipated increases in TrialMaster clients during fiscal 2005. We will look to selectively add experienced sales and marketing personnel in 2005 in an effort to increase our market penetration and to continue broadening our client base.

 

Rent expense increased by $6,138 during the first nine months of 2004. Our corporate office lease was extended through September 2005. In December 2001, we established a disaster recovery site at an IBM owned Co-Location facility in Atlanta, Georgia and will continue utilizing this facility for the foreseeable future since it is designed to ensure 100% system up-time and to provide system redundancy.

 

Legal and professional fees totaled $142,726 in 2004 compared with $92,594 during the first nine months of 2004 and fiscal 2003, respectively, an increase of approximately $50,132. The 2003 amount includes a credit of approximately $52,000 relating to the settlement of legal fees incurred during 2002. We expect on-going legal and professional fees to approximate what was experienced during the first nine months of 2004.

 

Selling, general and administrative expenses (“SGA”) were $89,648 during 2004 compared to $97,106 in 2003, a decrease of 7.7%. These expenses relate primarily to costs incurred in running our office day-to-day and other costs

 

19


Table of Contents

not directly related to other captioned items in our income statement, and include the cost of office equipment and supplies, the costs of attending conferences and seminars and other expenses incurred in the normal course of business. Included in the 2004 results of operations was the recovery of $20,000 of a previously impaired investment we made in Medical Network AG EMN, a Swiss healthcare related technology company. We originally established a 100% valuation allowance on our $355,000 investment during fiscal 2000. We do not expect to recover any additional funds from our investment in the future.

 

Net interest expense was $149,696 during 2004 versus $90,232 in fiscal 2003 an increase of $59,464 or 65.9%. We have used debt financing during 2004 to satisfy our working capital needs. During this period we issued $864,099 in promissory notes. When evaluating the cost of capital available to us in combination with our overall capital structure we concluded that this financing best fulfilled our short and long-term capital needs.

 

We sold additional Series C Convertible Preferred Stock during the first quarter of 2003 and we issued an additional 590,000 warrants to investors of our Series C Convertible Preferred Stock. The warrants were valued at $135,344 utilizing the Black-Scholes model. The net proceeds received in the Series C Convertible Preferred Stock Unit offering were allocated to the Series C Preferred Stock and we recognized a deemed dividend on preferred stock of $135,344 resulting in a charge to retained earnings and a credit to additional paid-in capital within our stockholders’ equity as of March 31, 2003.

 

We sold common stock during the first half of 2003 and we issued an additional 700,000 warrants to those investors. The warrants were valued at $160,577 utilizing the Black-Scholes model. The net proceeds received in the Series C Convertible Preferred Stock Unit offering were allocated to the Series C Preferred Stock and we recognized a deemed dividend on preferred stock of $160,577 resulting in a charge to retained earnings and a credit to additional paid-in capital within our stockholders’ equity as of September 30, 2003.

 

We issued 496,950 warrants to the placement agent of our Series Preferred C Stock as part of their compensation. The warrants were valued at $113,998 utilizing the Black-Scholes model. We recognized a deemed dividend on preferred stock of $113,998 resulting in a charge to retained earnings and a credit to additional paid-in capital within our stockholders’ equity as of September 30, 2003.

 

There were arrearages of $154,162 in 5% Series A Preferred Stock dividends, $77,334 in Series B Preferred Stock dividends and $202,474 in Series C Preferred Stock dividends at September 30, 2004, compared with arrearages of $153,600 in 5% Series A Preferred Stock dividends, $119,671 in Series B Preferred Stock dividends and $197,941 in Series C Preferred Stock dividends at September 30, 2003. We deducted $433,970 and $471,212 from Net Income (Loss) Attributable to Common Stockholders’ for the nine months ended September 30, 2004 and September 30 2003, respectively, relating to undeclared Series A, B and C Convertible Preferred Stock dividends.

 

The Three months Ended September 30, 2004 Compared With the Three months Ended September 30, 2003

 

Results of Operations

 

Revenues for the three months ended September 30, 2004 were $245,788 compared to $205,999 for the same period in 2003, an increase of 19.3%. The revenue increase can be attributed to an incremental increase in per project revenue.

 

The visibility of the EDC niche increased markedly during the first half of 2004. The biggest company in the EDC market, PhaseForward, completed an IPO and several other competitors were able to raise funds via private placements of their equity. This visibility in the investment community is likely to continue attracting capital to the segment. We believe that attention from the investment community is a good indicator that the EDC market will continue to attract capital and that industry growth is sustainable.

 

20


Table of Contents

Cost of goods sold increased to $62,117 for the three months ended September 30, 2004 compared to $56,279 for the comparable period in 2003. Cost of goods sold were approximately 25.3% of sales in 2004 compared to 27.3% in fiscal 2003.

 

Salaries and related expenses are our biggest expense at 65.5% of total Other Expenses for the three months ended September 2004. Salaries and related expenses totaled $428,700 in 2004 compared to $384,405 in 2003, an increase of 11.5%

 

Rent expense increased by $5,638 for the three months ended September 30, 2004. Our corporate office lease was extended through September 2005. In December 2001, we established a disaster recovery site at an IBM owned Co-Location facility in Atlanta, Georgia and will continue utilizing this facility for the foreseeable future since it is designed to ensure 100% system up-time and to provide system redundancy.

 

Legal and professional fees totaled $46,895 for the three months ended September 30, 2004 compared with $61,077 during the comparable period in fiscal 2003, a decrease of approximately $14,812. We expect on-going legal and professional fees to approximate what was experienced during the first half of 2004.

 

Selling, general and administrative expenses (“SGA”) were $17,068 for the three months ended September 30, 2004 compared to $29,643 for the comparable period in 2003, a decrease of 42.4%. These expenses relate primarily to costs incurred in running our office day-to-day and other costs not directly related to other captioned items in our income statement, and include the cost of office equipment and supplies, the costs of attending conferences and seminars and other expenses incurred in the normal course of business. Included in the 2004 results of operations was the recovery of $20,000 of a previously impaired investment we made in Medical Network AG EMN, a Swiss healthcare related technology company. We originally established a 100% valuation allowance on our $355,000 investment during fiscal 2000. We do not expect to recover any additional funds from our investment in the future.

 

Net interest expense was $60,796 during 2004 versus $31,810 for the three months ended September 30, 2004 and September 30, 2003, respectively, an increase of $28,986, or 91.1%. We have used debt financing during 2004 to satisfy our working capital needs. During the first nine months of 2004 we issued $864,099 in promissory notes. When evaluating the cost of capital available to us in combination with our overall capital structure we concluded that this financing best fulfilled our short and long-term capital needs.

 

There were arrearages of $51,762 in 5% Series A Preferred Stock dividends, $24,123 in Series B Preferred Stock dividends and $67,984 in Series C Preferred Stock dividends at September 30, 2004, compared with arrearages of $51,763 in 5% Series A Preferred Stock dividends, $40,329 in Series B Preferred Stock dividends and $67,985 in Series C Preferred Stock dividends at September 30, 2003. We deducted $143,869 and $160,077 from Net Income (Loss) Attributable to Common Stockholders’ for the three months ended September 30, 2004 and September 30 2003, respectively, relating to undeclared Series A, B and C Convertible Preferred Stock dividends.

 

Liquidity and Capital Resources

 

We have historically experienced negative cash flows and have relied primarily on the proceeds from the sale of debt and equity securities to fund our operations. In addition, we have utilized stock-based compensation as a means of paying for consulting and salary related expenses.

 

Cash and cash equivalents increased by $57,099 from $1,977 to $59,076 at September 30, 2004. This was the result of cash provided by financing activities of $1,456,599 offset by cash used in operating activities of approximately $1,374,419 and $25,081 used in investing activities. The significant components of the activity include a loss from operations of approximately $1,548,861 offset by non-cash expenses of $150,604 and approximately $1,456,999 we

 

21


Table of Contents

raised through the issuance of debt and equity securities offset by $25,081 used in investing activities and increases in cash of $23,839 from changes in working capital accounts.

 

We are not currently bound by any long or short-term agreements for the purchase or lease of capital expenditures. Any amounts expended for capital expenditures would be the result of an increase in the capacity needed to adequately service any increase in our business. To date we have paid for any needed additions to our capital equipment infrastructure from working capital funds and anticipate this being the case in the future. We do not presently have any commitments for capital expenditures.

 

We are currently in arrears on principal and interest payments owed totaling $514,735 on our 10% Convertible Notes. The terms of the notes provide a payment grace period of thirty days in which to make required semi-annual interest payments. We were in default effective January 30, 2002.

 

The Company had a recorded liability of $132,891 at September 30, 2004 for federal employment taxes. The Company had fully satisfied the liability as of November 12, 2004.

 

We have been operating with a cash burn rate since beginning our EDC operations. In order to manage cash flows, we have issued preferred stock and common stock to satisfy operating expenses and obligations. Between March 28, 2002 and March 2003 we sold 165,650 shares of our Series C Preferred Stock and warrants to purchase 3,513,000 shares of our common stock. Gross cash proceeds from this offering totaled $1,656,500. We accrued $333,092 in transaction related fees leaving net proceeds of approximately $1,423,409 of which $100,000 originally had been received as a bridge loan which was later converted at the shareholders request into shares of our Series C Preferred Stock.

 

From April 2003 through May 31, 2003 we sold an aggregate of 1,400,000 shares of our Common Stock and warrants to purchase 700,000 shares of our common stock for gross proceeds of $350,000. We accrued $35,000 in transaction fees leaving net proceeds to us of $315,000.

 

From July 2003 through December 31, 2003 we sold an aggregate of 2,484,000 shares of our common stock for gross proceeds of $621,000. We accrued $60,500 in transaction fees leaving net proceeds to us of $560,500.

 

From April 2004 through September 2004 we sold an aggregate of 2,600,000 shares of our common stock for gross proceeds of $650,000. We accrued $57,500 in transaction fees leaving net proceeds to us of $592,500.

 

Our selling efforts include marketing our products to several Fortune 500 pharmaceutical and medical device manufacturers and two of the largest CRO’s. We began providing services to some of these entities during 2003. These contracts should provide us the opportunity to limit our need for funding our operations via debt and equity capital. Obtaining contracts with clients of this size and reputation will also increase the credibility of the company.

 

We feel that the momentum established from new client acquisitions and our ability to retain clients for repeat engagements provide a good operating base from which to build during 2004 and fiscal 2005. We expect to continue increasing the level of resources deployed in our sales and marketing efforts. We embarked on a cost cutting program during fiscal 2000. That program became part of our organization’s identity and remains ingrained in our culture today. We feel that a combination of our lean operating environment and increased success in new client acquisition, coupled with our ability to retain our existing clients will allow us to compete effectively within the EDC market.

 

Because of the losses experienced since 1999 we have needed to continue utilizing the proceeds from the sale of debt and equity securities to fund our working capital needs. The capital markets since mid-2000 have provided a difficult climate for raising capital due to the decline in value of publicly held technology stocks and the resultant apprehension on the part of investors to invest in technology oriented firms. In addition, when available, capital has

 

22


Table of Contents

been expensive relative to the valuations that were afforded during the expansion of the Internet sector in 1999 and 2000. The softness in the capital markets coupled with the losses experienced have caused working capital shortfalls. We have used a combination of equity financing and short-term bridge loans to fund our working capital needs. Other than our current capital and capital we may raise from future debt or equity offerings or short-term bridge loans, we do not have any additional sources of working capital.

 

We will continue to require substantial funds to continue our research and development activities and to market, sell and commercialize our technology. We will need to raise substantial additional capital to fund our future operations. Our capital requirements will depend on many factors, including the problems, delays, expenses and complications frequently encountered by companies developing and commercializing new technologies; the progress of our research and development activities; the rate of technological advances; determinations as to the commercial potential of our technology under development; the status of competitive technology; the establishment of collaborative relationships; the success of our sales and marketing programs; the cost of filing, prosecuting and defending and enforcing patents and intellectual property rights; and other changes in economic, regulatory or competitive conditions in our planned business. Estimates about the adequacy of funding for our activities are based upon certain assumptions, including assumptions that the research and development programs relating to our technology can be conducted at projected costs and that progress towards broader commercialization of our technology will be timely and successful. There can be no assurance that changes in our research and development plans or other events will not result in accelerated or unexpected expenditures.

 

To satisfy our capital requirements, including ongoing future operations, we will seek to raise additional financing through debt and equity financings. There can be no assurance that any such funding will be available to us on favorable terms or at all. If adequate funds are not available when needed, we may be required to delay, scale back or eliminate some or all of our research and product development programs, and our business operations. If we are successful in obtaining additional financings, the terms of such financings may have the effect of diluting or adversely affecting the holdings or the rights of the holders of our common and preferred stock. Further, there can be no assurance that even if such additional capital is obtained or the planned cost reductions are implemented, that we will achieve positive cash flow or profitability or be able to continue as a business.

 

Our ability to continue in existence is dependent on our having sufficient financial resources to bring products and services to market. As a result of our significant losses, negative cash flows from operations, and accumulated deficits for the periods ending September 30, 2004, there is doubt about our ability to continue as a going concern. In addition, our auditors Greenberg and Company, included language which qualified their report regarding our ability to continue as a going concern in their report dated February 6, 2004.

 

IMPACT OF NEW ACCOUNTING STANDARDS

 

In March 2004, the Financial Accounting Standards Board (“FASB”) issued an exposure draft of Proposed Statement of Financial Accounting Standards, “Share-Based Payment”, an amendment of FASB Statement No. 123. This proposed Statement addresses the accounting for transactions in which an enterprise exchanges its equity instruments for employee services. It also addresses transactions in which an enterprise incurs liabilities that are based on the fair value of the enterprise’s equity instruments or that may be settled by the issuance of those equity instruments in exchange for employee services. For public entities, the cost of employee services received in exchange for equity instruments, including employee stock options, would be measured based on the grant-date fair value of those instruments. That cost would be recognized as compensation expense over the service period, which would normally be the vesting period.

 

If the proposed statement were adopted by us as currently proposed, it would require that compensation expense be recorded for employee stock options vesting or granted subsequent to May 31, 2005. The ultimate impact on diluted

 

23


Table of Contents

earnings per share of expensing stock options will be dependent upon the final pronouncement issued by the FASB, the method to be used for valuation of stock options determined by us and the amount of future stock option grants.

 

In March 2004, the FASB issued Proposed FASB Staff Position No. FAS 106-b (“FAS 106-b”) “Accounting and Disclosure Requirements Related to the Medicare Prescription Drug, Improvement and Modernization Act of 2003.” FAS 106-b provides guidance on the accounting for the effects of the Medicare Prescription Drug, Improvement and Modernization Act of 2003 for employers that sponsor post-retirement health care plans that provide prescription drug benefits. FAS 106-b will not have a material effect on us since we do not offer prescription drug benefits to any retirees at September 30, 2004.

 

CRITICAL ACCOUNTING POLICIES

 

The preparation of financial statements and related disclosures in conformity with accounting principles generally accepted in the United States requires management to make judgments, assumptions and estimates that affect the amounts reported. Note 2 of Notes to the Consolidated Financial Statements describes the significant accounting policies used in the preparation of the consolidated financial statements. Certain of these significant accounting policies are considered to be critical accounting policies, as defined below.

 

A critical accounting policy is defined as one that is both material to the presentation of our financial statements and requires management to make difficult, subjective or complex judgments that could have a material effect on our financial condition and results of operations. Specifically, critical accounting estimates have the following attributes: 1) we are required to make assumptions about matters that are highly uncertain at the time of the estimate; and 2) different estimates we could reasonably have used, or changes in the estimate that are reasonably likely to occur, would have a material effect on our financial condition or results of operations.

 

Estimates and assumptions about future events and their effects cannot be determined with certainty. We base our estimates on historical experience and on various other assumptions believed to be applicable and reasonable under the circumstances. These estimates may change as new events occur, as additional information is obtained and as our operating environment changes. These changes have historically been minor and have been included in the consolidated financial statements as soon as they became known. In addition, our Management is periodically faced with uncertainties, the outcomes of which are not within our control and will not be known for prolonged periods of time. Based on a critical assessment of its accounting policies and the underlying judgments and uncertainties affecting the application of those policies, our Management believes that our consolidated financial statements are fairly stated in accordance with accounting principles generally accepted in the United States (GAAP), and present a meaningful presentation of our financial condition and results of operations.

 

Our Management believes that the following are our critical accounting policies:

 

DEFERRED REVENUE

 

Deferred revenue represents cash advances received in excess of revenue earned on on-going contracts. Payment terms vary with each contract but may include an initial payment at the time the contract is executed, with future payments dependent upon the completion of certain contract phases or targeted milestones. In the event of contract cancellation, we are entitled to payment for all work performed through the point of cancellation.

 

REVENUE RECOGNITION POLICY

 

OmniComm’s revenue model is transaction-based and can be implemented either as an ASP (application service provider) or licensed for implementation by a customer such as a pharmaceutical company. Revenues are derived from

 

24


Table of Contents

the set-up of clinical trial engagements; on-going maintenance fees incurred throughout the duration of an engagement; fees for report writing and change orders. The clinical trials that are conducted using TrialMaster can last from a few months to several years. Most of the fees associated with our product including post-setup customer support in the form of maintenance charges are recognized ratably over the term of the clinical trial. Cost of sales is primarily comprised of programmer salaries and taxes and is expensed as incurred.

 

The Company recognizes sales, for both financial statement and tax purposes in accordance with SEC Staff Accounting Bulletin No. 104 “Revenue Recognition” (SAB 104). SAB 104 requires that revenues be recognized ratably over the life of a contract. In accordance with SAB 104 the Company will periodically record deferred revenues relating to advance payments in contracts.

 

STOCK BASED COMPENSATION.

 

Options granted to employees under our Stock Option Plan are accounted for by using the intrinsic value method under APB Opinion 25, Accounting for Stock Issued to Employees (APB 25). In October 1995, the Financial Accounting Standards Board issued Statement No.123, Accounting for Stock-Based Compensation (SFAS 123), which defines a fair value based method of accounting for stock options. All stock based compensation issued to individuals, other than employees and directors such compensation which is accounted for in accordance with APB 25, are accounted for in accordance with SFAS 123, as amended by SFAS 148.

 

ITEM 3. CONTROLS AND PROCEDURES

 

Based on their evaluation as of the end of the period covered by this Quarterly Report on Form 10-QSB, being September 30, 2004, the Company’s principal executive officer and principal financial officer have concluded that the Company’s disclosure controls and procedures as defined in Rules 13a-14(c) and 15d-14(c) under the Securities Exchange Act of 1934 (the Exchange Act) are effective to ensure that information required to be disclosed by the Company in reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in Securities and Exchange Commission rules and forms.

 

There were no significant changes in the Company’s internal controls or in other factors that could significantly affect these controls subsequent to the date of their evaluation and up to the filing date of this Quarterly Report on Form 10-QSB. There were no significant deficiencies or material weaknesses, and therefore there were no corrective actions taken.

 

It should be noted that any system of controls, however well designed and operated, can provide only reasonable, and not absolute, assurance that the objectives of the system are met. In addition, the design of any control system is based in part upon certain assumptions about the likelihood of future events. Because of these and other inherent limitations of control systems, there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions, regardless of how remote.

 

25


Table of Contents

PART II OTHER INFORMATION

 

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

 

From April 2004 through September 2004, we sold an aggregate of 2,600,000 shares of our common stock, pursuant to an exemption from registration under Regulation S of the Securities Act of 1933, as amended (the “Act”), resulting in gross proceeds of $650,000 to non-US persons, as that term is defined in Rule 901 of Regulation S. None of these investors were our affiliates. Noesis Capital Corp., an NASD member firm, acted as placement agent in the offering and as compensation therefore received a commission equal to 8% of the sales made by it, or an aggregate of $46,000, a non-accountable expense allowance equal to 2% of the sales made by it, or an aggregate of $11,500. In addition we will issue a warrant to purchase at $0.25 per share, 10% of the shares sold, or 260,000 shares of our common stock. At such time that warrant is issued, we will estimate the fair value of the warrants granted to Noesis Capital using the Black-Scholes option pricing model. Each certificate evidencing securities issued in the foregoing transaction included a legend to the effect that the securities were not registered under the Act, and could not be resold absent registration or the availability of an applicable exemption therefrom.

 

ITEM 6. EXHIBITS

 

The following documents are filed as a part of this report or are incorporated by reference to previous filings, if so indicated:

 

EXHIBIT NO.

 

DESCRIPTION


10.9   Employment Agreement between the Company and Randall G. Smith, dated September 1, 2004
10.10   Employment Agreement between the Company and Ronald T. Linares, dated September 1, 2004
10.11   Amended and Restated Promissory Note between the Company and Cornelis F. Wit, dated June 30, 2004
10.12   Amended and Restated Promissory Note between the Company and Guus van Kesteren, dated June 30, 2004
31.1   Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, promulgated under the Securities and Exchange Act of 1934, as amended.
31.2   Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, promulgated under the Securities and Exchange Act of 1934, as amended.
32.1   Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes Oxley Act of 2002.
32.2   Certification of Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes Oxley Act of 2002.

 

26


Table of Contents

SIGNATURES

 

In accordance with Section 13 or 15(d) of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

OmniComm Systems, Inc.
Registrant
By:  

/s/ Cornelis F. Wit


    Cornelis F. Wit, Director, Chief Executive Officer and President
Date:   November 12, 2004
By:  

/s/ Ronald T. Linares


   

Ronald T. Linares,

Vice President of Finance,

Chief Financial and Accounting Officer

Date:   November 12, 2004

 

27


Table of Contents

Exhibit Index

 

EXHIBIT NO.

 

DESCRIPTION


10.9   Employment Agreement between the Company and Randall G. Smith, dated September 1, 2004
10.10   Employment Agreement between the Company and Ronald T. Linares, dated September 1, 2004
10.11   Amended and Restated Promissory Note between the Company and Cornelis F. Wit, dated June 30, 2004
10.12   Amended and Restated Promissory Note between the Company and Guus van Kesteren, dated June 30, 2004
31.1   Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, promulgated under the Securities and Exchange Act of 1934, as amended.
31.2   Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, promulgated under the Securities and Exchange Act of 1934, as amended.
32.1   Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes Oxley Act of 2002.
32.2   Certification of Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes

EXHIBIT 10.9

 

EMPLOYMENT AGREEMENT

 

This Employment Agreement (the “Agreement”), dated as of September 1, 2004, between OmniComm Systems, Inc., a Delaware corporation, (the “Company”), and Randall G. Smith (the “Executive”).

 

WITNESSETH:

 

WHEREAS, the Executive has experience in managing at a senior level the technology of a publicly traded company (or a division of such a company) involved in the clinical trials business;

 

WHEREAS, the parties acknowledge that the Executive’s abilities and services are unique and essential to the prospects of the Company; and,

 

WHEREAS, in light of the foregoing, the Company desires to employ the Executive as its Chief Technology Officer and the Executive desires to accept such employment.

 

NOW, THEREFORE, the parties hereto agree as follows:

 

1. Employment . The Company hereby employs the Executive and the Executive hereby accepts employment upon the terms and conditions hereinafter set forth.

 

2. Term and Termination . This Agreement shall commence on September 1, 2004 for a term of one-year and shall automatically renew for successive one-year terms unless terminated by:

 

  (a) the death or disability of the Executive. Disability shall mean the Executive’s inability, due to sickness or injury, to perform effectively his duties hereunder for a period of at least 90 consecutive days;

 

  (b) thirty (30) days after notice is given by the Company to the Executive after a material breach hereof by the Executive; or,

 

  (c) thirty (30) days after notice is given by the Executive to the Company after a material breach hereof by the Company.

 

The exercise of the Company’s or the Executive’s right to terminate this Agreement pursuant to clause (b) or (c) hereof, as the case may be, shall not abrogate the rights and remedies of the terminating party in respect of the breach giving rise to such termination.

 

3. Salary . For all services rendered under this Agreement:

 

  (a) During the term of his employment, the Company shall pay the Executive an annual salary of $150,000. The Executive’s salary may be paid in the form of cash and/or stock, as agreed upon by the parties. This amount may be increased at the discretion of the Board of Directors and shall be adjusted to compensate for annual cost of living increases.

 

  (b) During the term of his employment, the Executive shall be entitled to participate in employee benefit plans or programs of the Company, if any, to the extent the Executive is eligible to participate thereunder. Such plans and programs shall include, but not be limited to, the following:

 

  i. major medical health insurance for the Executive, his spouse and two children; and

 

  ii. four weeks paid vacation.


  (c) The Executive shall be permitted to participate in the Company’s stock option plan.

 

  (d) The Company shall also pay the Executive a bonus based upon achieving technology related milestones set forth in a particular calendar year. The Executive shall be entitled to receive a bonus to be agreed upon by the Executive and the Company’s Board of Directors. The Company’s Board of Directors and the Executive shall agree upon the milestones and if the Executive meets the milestone conditions, he shall be paid 30 days after the end of the Company’s calendar year.

 

  (e) The Executive shall also be entitled to severance pay equal to six (6) months salary and benefits in the event of termination by the Company for any reason other than commission of a felony or a crime involving moral turpitude relating to services provided to the Company, or termination by the Company pursuant to Paragraph 2(c). Options which have vested prior to the date of termination shall remain exercisable during the severance period. Unvested options shall terminate in accordance with the terms of the respective Stock Option Agreements.

 

4. Duties. The Executive shall be employed as Chief Technology Officer of the Company and, subject to the direction of the Board of Directors and the Company’s officers designated by the Board of Directors, shall perform and discharge well and faithfully the duties which may be assigned to him from time to time by the Company in connection with the conduct of its business. If the Executive is elected or appointed a director of the Company or any subsidiary thereof during the term of this Agreement, the Executive will serve in such capacity without further compensation.

 

5. Extent of Services. Except as set forth below, the Executive shall devote his entire time, attention and energies to the business of the Company and shall not during the term of this Agreement be engaged, whether or not during normal business hours, in any other business or professional activity, whether or not such activity is pursued for gain, profit, or other pecuniary advantage. Notwithstanding the foregoing, the Executive shall be allowed to serve on the Board of Directors of other companies so long as such Board participation does not interfere with the Executive fulfilling his duties to the Company and the Executive obtains the prior written approval of the Company’s Board of Directors. In addition, the Executive shall be allowed to provide consulting services to other companies so long as he obtains the prior written approval of the Company’s Board of Directors, turns over to the Company the entire amount of the compensation he receives as a result of providing such services, and provides such services no more than three (3) days per month.

 

6. Disclosure of Information. The Executive recognizes and acknowledges that the Company’s trade secrets and proprietary information and processes, as they may exist from time to time, are valuable, special and unique assets of the Company’s business, access to and knowledge of which are essential to the performance of the Executive’s duties hereunder. The Executive will not, during or after the term of his employment by the Company, in whole or in part, disclose such secrets, information or processes to any person, firm, corporation, association or other entity for any reason or purpose whatsoever, nor shall the Executive make use of any such property for his own purposes or for the benefit of any person, firm, corporation or other entity except the Company under any circumstances during or after the term of his employment, provided that after the term of his employment these restrictions shall not apply to such secrets, information and processes which are then in the public domain provided that the Executive was not responsible, directly or indirectly, for such secrets, information or processes entering the public domain without the Company’s consent. The Executive agrees to hold as the Company’s property, all memoranda, books, papers, letters, formulas and other data, and all copies thereof and therefrom, in any way relating to the Company’s business and affairs, whether made by him or otherwise coming into his possession, and on termination of his employment, or on demand of the Company, at any time, to deliver the same to the Company. In the event an action is instituted and prior knowledge is an issue, it shall be the obligation of the Executive to prove by clear and convincing evidence that the confidential information disclosed was in the public domain, was already known by the Executive prior to his employment with the Company, or was developed independently by the Executive.

 

2


7. Inventions. The Executive hereby sells, transfers and assigns to the Company or to any person, or entity designated by the Company, all of the entire right, title and interest of the Executive in and to all inventions, ideas, disclosures and improvements, whether patented or unpatented, and copyrightable material, made or conceived by the Executive, solely or jointly, or in whole or in part, during the term hereof which (i) relate to methods, apparatus, designs, products, processes or devices sold, leased, used or under construction or development by the Company or any subsidiary, or (ii) otherwise relate to or pertain to the business, functions or operations of the Company or any subsidiary, or (iii) arise wholly or partly from the efforts of the Executive during the term hereof. The Executive shall communicate promptly and disclose to the Company, in such form as the Company requests, all information, details and data pertaining to the aforementioned inventions, ideas, disclosures and improvements; and, whether during the term hereof or thereafter, the Executive shall execute and deliver to the Company such formal transfers and assignments and such other papers and documents as maybe required of the Executive at the Company’s expense to permit the Company or any person or entity designated by the Company to file and prosecute the patent applications and, as to copyrightable material, to obtain copyright thereon. Any invention by the Executive within one (1) year following the termination of this Agreement shall be deemed to fall within the provisions of this paragraph unless proved by the Executive to have been first conceived and made following such termination.

 

8. Covenant Not to Compete.

 

  (a) During the term hereof and for a period of one (1) year thereafter, the Executive shall not compete, directly or indirectly, with the Company, interfere with, disrupt or attempt to disrupt the relationship, contractual or otherwise, between the Company and any customer, client, supplier, consultant, or employee of the Company and any customer, client, supplier, consultant or employee of the Company, including, without limitation, employing or being an investor (representing more than 5% equity interest) in, or officer, director, or consultant to, any person or entity which employs any former key or technical employee whose employment with the Company was terminated after the date which is one year prior to the date of termination of the Executive’s employment therewith. An activity competitive with an activity engaged in by the Company shall mean performing services whether as an employee, officer, consultant, director, partner, or sole proprietor for any person or entity engaged in the business then engaged in by the Company, which services involve the development and marketing of a web-based system to collect, manage, and compile clinical trial and research data.

 

  (b) It is the desire and intent of the parties that the provisions of this Section shall be enforced to the fullest extent permissible under the laws and public policies applied in each jurisdiction in which enforcement is sought. Accordingly, if any particular portion of this Section shall be adjudicated to be invalid or unenforceable, this Section shall be deemed amended to delete therefrom the portion thus adjudicated to be invalid or unenforceable, such deletion to apply only with respect to the operation of this Section in the particular jurisdiction in which such adjudication is made.

 

  (c) Nothing in this Section shall reduce or abrogate the Executive’s obligations during the term of this Agreement under Sections 4 and 5 hereof.

 

9. Remedies. If there is a breach or threatened breach of the provisions of Section 6, 7 or 8 of this Agreement, the Company shall be entitled to an injunction restraining the Executive from such breach. Nothing herein shall be construed as prohibiting the Company from pursuing any other remedies for such breach or threatened breach.

 

10. Assignment. This Agreement may not be assigned by any party hereto; provided that the Company may assign this Agreement:

 

  (a) to an affiliate so long as such affiliate assumes the Company’s obligations hereunder; provided that no such assignment shall discharge the Company of its obligations herein, or

 

3


  (b) in connection with a merger or consolidation involving the Company or a sale of more than 50% of the Company’s securities or assets, to the surviving corporation or purchaser as the case may be, so long as such assignee assumes the Company’s obligations thereunder.

 

11. Notices. Any notice required or permitted to be given under this Agreement shall be sufficient if in writing and sent by registered mail to the Executive at his residence at:

 

Randall G. Smith

214 N. Park Ave.

Batesville, IN 47006

 

and to the Company at:

 

OmniComm Systems, Inc.

2555 Davie Road, Suite 110-B

Davie, Florida 33317

Attention: Chief Financial Officer

 

12. Waiver of Breach. A waiver by the Company or the Executive of a breach of any provision of this Agreement by the other party shall not operate or be construed as a waiver of any subsequent breach by the other party.

 

13. Entire Agreement. This instrument contains the entire agreement of the parties. It may be changed only by an agreement in writing signed by a party against whom enforcement of any waiver, change, modification, extension or discharge is sought.

 

14. Governing Law. This Agreement shall be construed in accordance with the laws of the State of Florida. All questions with respect to the construction hereof and the rights and liabilities of the parties hereto shall be governed by the laws of the State of Florida. Any action or proceeding arising out of or relating hereto shall be brought in Miami-Dade County, State of Florida.

 

IN WITNESS WHEREOF , the parties hereto have executed this Agreement as of the day and year first hereinabove written.

 

OmniComm Systems, Inc.
By:  

/s/ Cornelis. F. Wit


    Cornelis Wit
    Chief Executive Officer

 

Executive

 

   

/s/ Randall G. Smith


    Randall G. Smith

 

4

EXHIBIT 10.10

 

EMPLOYMENT AGREEMENT

 

This Employment Agreement (the “Agreement”), dated as of September 1, 2004, between OmniComm Systems, Inc., a Delaware corporation, (the “Company”), and Ronald Linares (the “Executive”).

 

WITNESSETH:

 

WHEREAS, the Executive has experience in managing at a senior level the financial activities of a publicly traded company (or a division of such a company) involved in the clinical trials business;

 

WHEREAS, the parties acknowledge that the Executive’s abilities and services are unique and essential to the prospects of the Company; and,

 

WHEREAS, in light of the foregoing, the Company desires to employ the Executive as its Chief Financial Officer and the Executive desires to accept such employment.

 

NOW, THEREFORE, the parties hereto agree as follows:

 

1. Employment . The Company hereby employs the Executive and the Executive hereby accepts employment upon the terms and conditions hereinafter set forth.

 

2. Term and Termination . This Agreement shall commence on September 1, 2004 for a term of one-year and shall automatically renew for successive one-year terms unless terminated by:

 

  (a) the death or disability of the Executive. Disability shall mean the Executive’s inability, due to sickness or injury, to perform effectively his duties hereunder for a period of at least 90 consecutive days;

 

  (b) thirty (30) days after notice is given by the Company to the Executive after a material breach hereof by the Executive; or,

 

  (c) thirty (30) days after notice is given by the Executive to the Company after a material breach hereof by the Company.

 

The exercise of the Company’s or the Executive’s right to terminate this Agreement pursuant to clause (b) or (c) hereof, as the case may be, shall not abrogate the rights and remedies of the terminating party in respect of the breach giving rise to such termination.

 

3. Salary . For all services rendered under this Agreement:

 

  (a) During the term of his employment, the Company shall pay the Executive an annual salary of $161,000. The Executive’s salary may be paid in the form of cash and/or stock, as agreed upon by the parties. This amount may be increased at the discretion of the Board of Directors and shall be adjusted to compensate for annual cost of living increases.

 

  (b) During the term of his employment, the Executive shall be entitled to participate in employee benefit plans or programs of the Company, if any, to the extent the Executive is eligible to participate thereunder. Such plans and programs shall include, but not be limited to, the following:

 

  i. major medical health insurance for the Executive, his spouse and two children; and

 

  ii. four weeks paid vacation.

 

  (c) The Executive shall be permitted to participate in the Company’s stock option plan.

 

  (d) The Company shall also pay the Executive a bonus based upon achieving financial milestones set forth in a particular calendar year. The Executive shall be entitled to receive a bonus to be agreed upon by the Executive and the Company’s Board of Directors. The Company’s Board of Directors and the Executive shall agree upon the milestones and if the Executive meets the milestone conditions, he shall be paid 30 days after the end of the Company’s calendar year.


  (e) The Executive shall also be entitled to severance pay equal to six (6) months salary and benefits in the event of termination by the Company for any reason other than commission of a felony or a crime involving moral turpitude relating to services provided to the Company, or termination by the Company pursuant to Paragraph 2(c). Options which have vested prior to the date of termination shall remain exercisable during the severance period. Unvested options shall terminate in accordance with the terms of the respective Stock Option Agreements.

 

4. Duties. The Executive shall be employed as Chief Financial Officer of the Company and, subject to the direction of the Board of Directors and the Company’s officers designated by the Board of Directors, shall perform and discharge well and faithfully the duties which may be assigned to him from time to time by the Company in connection with the conduct of its business. If the Executive is elected or appointed a director of the Company or any subsidiary thereof during the term of this Agreement, the Executive will serve in such capacity without further compensation.

 

5. Extent of Services. Except as set forth below, the Executive shall devote his entire time, attention and energies to the business of the Company and shall not during the term of this Agreement be engaged, whether or not during normal business hours, in any other business or professional activity, whether or not such activity is pursued for gain, profit, or other pecuniary advantage. Notwithstanding the foregoing, the Executive shall be allowed to serve on the Board of Directors of other companies so long as such Board participation does not interfere with the Executive fulfilling his duties to the Company and the Executive obtains the prior written approval of the Company’s Board of Directors. In addition, the Executive shall be allowed to provide consulting services to other companies so long as he obtains the prior written approval of the Company’s Board of Directors, turns over to the Company the entire amount of the compensation he receives as a result of providing such services, and provides such services no more than three (3) days per month.

 

6. Disclosure of Information. The Executive recognizes and acknowledges that the Company’s trade secrets and proprietary information and processes, as they may exist from time to time, are valuable, special and unique assets of the Company’s business, access to and knowledge of which are essential to the performance of the Executive’s duties hereunder. The Executive will not, during or after the term of his employment by the Company, in whole or in part, disclose such secrets, information or processes to any person, firm, corporation, association or other entity for any reason or purpose whatsoever, nor shall the Executive make use of any such property for his own purposes or for the benefit of any person, firm, corporation or other entity except the Company under any circumstances during or after the term of his employment, provided that after the term of his employment these restrictions shall not apply to such secrets, information and processes which are then in the public domain provided that the Executive was not responsible, directly or indirectly, for such secrets, information or processes entering the public domain without the Company’s consent. The Executive agrees to hold as the Company’s property, all memoranda, books, papers, letters, formulas and other data, and all copies thereof and therefrom, in any way relating to the Company’s business and affairs, whether made by him or otherwise coming into his possession, and on termination of his employment, or on demand of the Company, at any time, to deliver the same to the Company. In the event an action is instituted and prior knowledge is an issue, it shall be the obligation of the Executive to prove by clear and convincing evidence that the confidential information disclosed was in the public domain, was already known by the Executive prior to his employment with the Company, or was developed independently by the Executive.

 

7. Inventions. The Executive hereby sells, transfers and assigns to the Company or to any person, or entity designated by the Company, all of the entire right, title and interest of the Executive in and to all inventions, ideas, disclosures and improvements, whether patented or unpatented, and copyrightable material, made or conceived by the Executive, solely or jointly, or in whole or in part, during the term hereof which (i) relate to

 

2


methods, apparatus, designs, products, processes or devices sold, leased, used or under construction or development by the Company or any subsidiary, or (ii) otherwise relate to or pertain to the business, functions or operations of the Company or any subsidiary, or (iii) arise wholly or partly from the efforts of the Executive during the term hereof. The Executive shall communicate promptly and disclose to the Company, in such form as the Company requests, all information, details and data pertaining to the aforementioned inventions, ideas, disclosures and improvements; and, whether during the term hereof or thereafter, the Executive shall execute and deliver to the Company such formal transfers and assignments and such other papers and documents as maybe required of the Executive at the Company’s expense to permit the Company or any person or entity designated by the Company to file and prosecute the patent applications and, as to copyrightable material, to obtain copyright thereon. Any invention by the Executive within one (1) year following the termination of this Agreement shall be deemed to fall within the provisions of this paragraph unless proved by the Executive to have been first conceived and made following such termination.

 

8. Covenant Not to Compete.

 

  (a) During the term hereof and for a period of one (1) year thereafter, the Executive shall not compete, directly or indirectly, with the Company, interfere with, disrupt or attempt to disrupt the relationship, contractual or otherwise, between the Company and any customer, client, supplier, consultant, or employee of the Company and any customer, client, supplier, consultant or employee of the Company, including, without limitation, employing or being an investor (representing more than 5% equity interest) in, or officer, director, or consultant to, any person or entity which employs any former key or technical employee whose employment with the Company was terminated after the date which is one year prior to the date of termination of the Executive’s employment therewith. An activity competitive with an activity engaged in by the Company shall mean performing services whether as an employee, officer, consultant, director, partner, or sole proprietor for any person or entity engaged in the business then engaged in by the Company, which services involve the development and marketing of a web-based system to collect, manage, and compile clinical trial and research data.

 

  (b) It is the desire and intent of the parties that the provisions of this Section shall be enforced to the fullest extent permissible under the laws and public policies applied in each jurisdiction in which enforcement is sought. Accordingly, if any particular portion of this Section shall be adjudicated to be invalid or unenforceable, this Section shall be deemed amended to delete therefrom the portion thus adjudicated to be invalid or unenforceable, such deletion to apply only with respect to the operation of this Section in the particular jurisdiction in which such adjudication is made.

 

  (c) Nothing in this Section shall reduce or abrogate the Executive’s obligations during the term of this Agreement under Sections 4 and 5 hereof.

 

9. Remedies. If there is a breach or threatened breach of the provisions of Section 6, 7 or 8 of this Agreement, the Company shall be entitled to an injunction restraining the Executive from such breach. Nothing herein shall be construed as prohibiting the Company from pursuing any other remedies for such breach or threatened breach.

 

10. Assignment. This Agreement may not be assigned by any party hereto; provided that the Company may assign this Agreement:

 

  (a) to an affiliate so long as such affiliate assumes the Company’s obligations hereunder; provided that no such assignment shall discharge the Company of its obligations herein, or

 

  (b) in connection with a merger or consolidation involving the Company or a sale of more than 50% of the Company’s securities or assets, to the surviving corporation or purchaser as the case may be, so long as such assignee assumes the Company’s obligations thereunder.

 

3


11. Notices. Any notice required or permitted to be given under this Agreement shall be sufficient if in writing and sent by registered mail to the Executive at his residence at:

 

Ronald Linares

1000 NW 190 Ave

Pembroke Pines, FL 33029

 

and to the Company at:

 

OmniComm Systems, Inc.

2555 Davie Road, Suite 110-B

Davie, Florida 33317

Attention: Chief Executive Officer

 

12. Waiver of Breach. A waiver by the Company or the Executive of a breach of any provision of this Agreement by the other party shall not operate or be construed as a waiver of any subsequent breach by the other party.

 

13. Entire Agreement. This instrument contains the entire agreement of the parties. It may be changed only by an agreement in writing signed by a party against whom enforcement of any waiver, change, modification, extension or discharge is sought.

 

14. Governing Law. This Agreement shall be construed in accordance with the laws of the State of Florida. All questions with respect to the construction hereof and the rights and liabilities of the parties hereto shall be governed by the laws of the State of Florida. Any action or proceeding arising out of or relating hereto shall be brought in Miami-Dade County, State of Florida.

 

IN WITNESS WHEREOF , the parties hereto have executed this Agreement as of the day and year first hereinabove written.

 

OmniComm Systems, Inc.
By:  

/s/ Cornelis F. Wit


    Cornelis Wit
    Chief Executive Officer

 

Executive

 

   

/s/ Ronald Linares


    Ronald Linares

 

4

EXHIBIT 10.11

 

PROMISSORY NOTE

 

$364,759.00

Broward County, Florida

June 30, 2004

 

FOR VALUE RECEIVED, the undersigned, (hereinafter referred to as the (“Maker”) promises to pay to the order of Guus van Kesteren, its successors or assigns, (hereinafter referred to as “Payee”), the principal sum of THREE HUNDRED SIXTY FOUR THOUSAND SEVEN HUNDRED AND FIFTY NINE/100 DOLLARS ($364,759.00), together with interest on the principal balance from time to time outstanding, at the rate of nine percent (9.00%) per annum; principal and interest shall be payable as follows: (i) one-half (1/2) of the principal sum shall be payable upon the closing of any financing by Maker resulting in gross proceeds to the Maker in excess of $2,000,000, and (ii) the balance of the principal sum, together with accrued interest, shall be paid no later than October 31, 2006.

 

This Promissory Note hereby replaces and supercedes the promissory note previously issued to the Payee by the Maker, including: (i) that certain note in the principal amount of $196,644.00. originally dated August 31, 2001, (ii) that certain note in the principal amount of $50,000 dated December 31, 2003, (iii) that certain note in the principal amount of $71,000 dated March 25, 2004 and (iv) that certain note in the principal amount of $35,000 dated June 4, 2004..

 

In the event that the Maker defaults in the payment of any payment of the principal sum or interest owing hereunder when and as the same shall become due and payable and such default shall continue for a period of 15 days, then this Promissory Note shall be in default and the entire principal sum and all accrued interest shall become due and payable at once without notice and demand at the option of the Payee. While in default, amounts outstanding under this Promissory Note shall bear interest at the rate of twelve percent (12%) per annum.

 

This Promissory Note may be prepaid in whole or in part at any time without penalty or premium. All payments made shall first be applied to accrued and unpaid interest and then to principal. Any prepayment shall require payment of all accrued interest thereon.

 

In the event of an action to enforce this Promissory Note is commenced in a court of competent jurisdiction or in the event recourse to any court shall be deemed necessary by Payee or Payee deems it necessary to employ legal counsel in order to collect or enforce the terms and provisions hereof for any reason, including but not limited to the filing of a proof(s) of claim or any other proceedings under the Acts of Congress relating to Bankruptcy Proceedings or in any other type of receivership or insolvency proceedings, Payee shall be entitled to reasonable attorney’s fees (through and including any appellate proceedings) and all costs and expenses incurred by Payee in collecting or enforcing payment hereof.

 

The Maker and any endorsers, sureties, guarantors, and all others who are, or may become liable for the payment hereof, (a) severally waive presentment for payment, demand, notice of protest of this Promissory Note, and all other notices in connection with the delivery, acceptance, performance, default, or enforcement of the payment of this Promissory Note, (b) expressly consent to all extensions of time, renewals, postponements of time of payment of this Promissory Note or other modifications hereof from time to time prior to or after the day they became due without notice, consent or consideration to any of the foregoing, (c) expressly agree to the addition or release of any party or person primarily or secondarily liable hereon, (d) expressly agree that the Payee shall not be required first to institute any suit, or to exhaust its remedies against the undersigned or any other person or party to become liable hereunder in order to enforce the payment of this Promissory Note, and (e) expressly agree that, notwithstanding the occurrence of any of the foregoing (except the express written release by the Payee of any such person), the Maker shall be and remain, directly and primarily liable for all sums due under this Promissory Note.


Notwithstanding any other provisions of this Promissory Note or any other instrument executed in connection with the loan evidenced here by, it is expressly agreed that the amounts payable under this Promissory Note or under the other aforesaid instruments for the payment of interest or any other payment in the nature of or which would be considered as interest or other charge for the use or loan of money shall not exceed the highest rate allowed by the laws of the State of Florida, from time to time, and in the event the provisions of this Promissory Note or of such other instrument referred to above in this paragraph with respect to the payment of interest or other payments in the nature of or which would be considered as interest or other charge for the use or loan of money shall result in exceeding such limitation, then the excess over such limitation shall not be payable and the amount otherwise agreed to have been paid shall be reduced by the excess so that such limitation will not be exceeded. If any payment is actually made which shall result in such limitation being exceeded, the amount of the excess shall constitute and be treated as a payment on the principal hereof and shall operate to reduce such principal by the amount of such excess, or if in excess of the principal indebtedness, such excess shall be refunded.

 

This Promissory Note shall be construed in accordance with the laws of the State of Florida.

 

MAKER HEREBY KNOWINGLY, VOLUNTARILY AND INTENTIONALLY WAIVES THE RIGHT EITHER MAY HAVE TO A TRIAL BY JURY IN RESPECT TO ANY LITIGATION BASED HEREUNDER, OR ARISING OUT OF, OR IN CONNECTION WITH THIS PROMISSORY NOTE OR ANY DOCUMENT EXECUTED IN CONNECTION HEREWITH, OR ANY COURSE OF CONDUCT, COURSE OF DEALING, STATEMENTS (WHETHER VERBAL OR WRITTEN), OR ACTIONS OF EITHER THE MAKER OR LENDER. THIS PROVISION IS A MATERIAL INDUCEMENT FOR THE PAYEE TO EXTEND THE CREDIT EVIDENCED BY THIS NOTE.

 

MAKER:

 

OMNICOMM SYSTEMS, INC.

/s/ Ronald T. Linares


Ronald T. Linares
Chief Financial Officer

 

2

EXHIBIT 10.12

 

PROMISSORY NOTE

 

$483,984.00

Broward County, Florida

June 30, 2004

 

FOR VALUE RECEIVED, the undersigned, (hereinafter referred to as the (“Maker”) promises to pay to the order of Cornelis Wit., its successors or assigns, (hereinafter referred to as “Payee”), the principal sum of FOUR HUNDRED EIGHTY THREE THOUSAND NINE HUNDRED AND EIGHTY FOUR/100 DOLLARS ($483,984.00), together with interest on the principal balance from time to time outstanding, at the rate of nine percent (9.00%) per annum; principal and interest shall be payable as follows: (i) one-half (1/2) of the principal sum shall be payable upon the closing of any financing by Maker resulting in gross proceeds to the Maker in excess of $2,000,000, and (ii) the balance of the principal sum, together with accrued interest, shall be paid no later than October 31, 2006.

 

This Promissory Note hereby replaces and supercedes the promissory note previously issued to the Payee by the Maker, including: (i) that certain note in the principal amount of $50,000.00. December 31, 2003, (ii) that certain note in the principal amount of $100,000 dated June 30 , 2003, (iii) that certain note in the principal amount of $60,000 dated July 18, 2003, (iv) that certain note in the principal amount of $56,000 dated August 18, 2003, (v) that certain note in the principal amount of $30,000 dated October 13, 2003, (vi) that certain note in the principal amount of $3,000 dated November 21, 2003, (vii) that certain note in the principal amount of $105,000 dated March 31, 2004 and (viii) that certain note in the principal amount of $48,500 dated June 30, 2004.

 

In the event that the Maker defaults in the payment of any payment of the principal sum or interest owing hereunder when and as the same shall become due and payable and such default shall continue for a period of 15 days, then this Promissory Note shall be in default and the entire principal sum and all accrued interest shall become due and payable at once without notice and demand at the option of the Payee. While in default, amounts outstanding under this Promissory Note shall bear interest at the rate of twelve percent (12%) per annum.

 

This Promissory Note may be prepaid in whole or in part at any time without penalty or premium. All payments made shall first be applied to accrued and unpaid interest and then to principal. Any prepayment shall require payment of all accrued interest thereon.

 

In the event of an action to enforce this Promissory Note is commenced in a court of competent jurisdiction or in the event recourse to any court shall be deemed necessary by Payee or Payee deems it necessary to employ legal counsel in order to collect or enforce the terms and provisions hereof for any reason, including but not limited to the filing of a proof(s) of claim or any other proceedings under the Acts of Congress relating to Bankruptcy Proceedings or in any other type of receivership or insolvency proceedings, Payee shall be entitled to reasonable attorney’s fees (through and including any appellate proceedings) and all costs and expenses incurred by Payee in collecting or enforcing payment hereof.

 

The Maker and any endorsers, sureties, guarantors, and all others who are, or may become liable for the payment hereof, (a) severally waive presentment for payment, demand, notice of protest of this Promissory Note, and all other notices in connection with the delivery, acceptance, performance, default, or enforcement of the payment of this Promissory Note, (b) expressly consent to all extensions of time, renewals, postponements of time of payment of this Promissory Note or other modifications hereof from time to time prior to or after the day they became due without notice, consent or consideration to any of the foregoing, (c) expressly agree to the addition or release of any party or person primarily or secondarily liable hereon, (d) expressly agree that the Payee shall not be required first to institute any suit, or to exhaust its remedies against the undersigned or any other person or party to become liable hereunder in order to enforce the payment of this Promissory Note, and (e) expressly agree that, notwithstanding the occurrence of any of the foregoing (except the express written release by the Payee of any such person), the Maker shall be and remain, directly and primarily liable for all sums due under this Promissory Note.


Notwithstanding any other provisions of this Promissory Note or any other instrument executed in connection with the loan evidenced here by, it is expressly agreed that the amounts payable under this Promissory Note or under the other aforesaid instruments for the payment of interest or any other payment in the nature of or which would be considered as interest or other charge for the use or loan of money shall not exceed the highest rate allowed by the laws of the State of Florida, from time to time, and in the event the provisions of this Promissory Note or of such other instrument referred to above in this paragraph with respect to the payment of interest or other payments in the nature of or which would be considered as interest or other charge for the use or loan of money shall result in exceeding such limitation, then the excess over such limitation shall not be payable and the amount otherwise agreed to have been paid shall be reduced by the excess so that such limitation will not be exceeded. If any payment is actually made which shall result in such limitation being exceeded, the amount of the excess shall constitute and be treated as a payment on the principal hereof and shall operate to reduce such principal by the amount of such excess, or if in excess of the principal indebtedness, such excess shall be refunded.

 

This Promissory Note shall be construed in accordance with the laws of the State of Florida.

 

MAKER HEREBY KNOWINGLY, VOLUNTARILY AND INTENTIONALLY WAIVES THE RIGHT EITHER MAY HAVE TO A TRIAL BY JURY IN RESPECT TO ANY LITIGATION BASED HEREUNDER, OR ARISING OUT OF, OR IN CONNECTION WITH THIS PROMISSORY NOTE OR ANY DOCUMENT EXECUTED IN CONNECTION HEREWITH, OR ANY COURSE OF CONDUCT, COURSE OF DEALING, STATEMENTS (WHETHER VERBAL OR WRITTEN), OR ACTIONS OF EITHER THE MAKER OR LENDER. THIS PROVISION IS A MATERIAL INDUCEMENT FOR THE PAYEE TO EXTEND THE CREDIT EVIDENCED BY THIS NOTE.

 

MAKER:

 

OMNICOMM SYSTEMS, INC.

/s/ Ronald T. Linares


Ronald T. Linares
Chief Financial Officer

 

2

EXHIBIT 31.1

 

CERTIFICATION OF CHIEF EXECUTIVE OFFICER

 

PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

 

I, CORNELIS WIT, certify that:

 

1. I have reviewed this quarterly report on Form 10-QSB of OmniComm Systems, Inc.;

 

2. Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances made, not misleading with respect to the period covered by this quarterly report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this quarterly report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this quarterly report;

 

4. The registrant’s other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and we have:

 

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designated under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this quarterly report is being prepared;

 

(b) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this quarterly report based on such evaluation; and

 

(c) Disclosed in this quarterly report any changes in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting.

 

5. The registrant’s other certifying officers and I have disclosed, based on our most recent evaluation of the internal controls over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

(a) All significant deficiencies and material weaknesses in the design or operation of internal controls over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial data and have identified for the registrant’s auditors any material weaknesses in internal controls; and

 

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal controls over financial reporting.

 

By:  

/s/ Cornelis Wit


    Cornelis Wit
    Chief Executive Officer

 

November 12, 2004

EXHIBIT 31.2

 

CERTIFICATION OF CHIEF FINANCIAL OFFICER

 

PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

 

I, RONALD T. LINARES, certify that:

 

1. I have reviewed this quarterly report on Form 10-QSB of OmniComm Systems, Inc.;

 

2. Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances made, not misleading with respect to the period covered by this quarterly report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this quarterly report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this quarterly report;

 

4. The registrant’s other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and we have:

 

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designated under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this quarterly report is being prepared;

 

(b) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this quarterly report based on such evaluation; and

 

(c) Disclosed in this quarterly report any changes in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting.

 

5. The registrant’s other certifying officers and I have disclosed, based on our most recent evaluation of the internal controls over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

(a) All significant deficiencies and material weaknesses in the design or operation of internal controls over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial data and have identified for the registrant’s auditors any material weaknesses in internal controls; and

 

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal controls over financial reporting.

 

By:  

/s/ Ronald T. Linares


    Ronald T. Linares
    Chief Financial Officer

 

November 12, 2004

EXHIBIT 32.1

 

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Quarterly Report on Form 10-QSB of OmniComm Systems, Inc. (the “Company”) for the quarter ended September 30, 2004, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, being, Cornelis F. Wit, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

 

  1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

  2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

/s/ Cornelis F. Wit


Cornelis F. Wit
President, Chief Executive Officer and Director

 

November 12, 2004

EXHIBIT 32.2

 

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Quarterly Report on Form 10-QSB of OmniComm Systems, Inc. (the “Company”) for the quarter ended September 30, 2004, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, being, Ronald T. Linares, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

 

  1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

  2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

/s/ Ronald T. Linares


Ronald T. Linares
Vice President and Chief Financial Officer

 

November 12, 2004